Processing 00000000.tx.1: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells Thomas Rasmussen, Lotta Hansson, Anders sterborg, Hans Erik Johnsen, and Hkan Mellstedt From Herlev Hospital, University of Copenhagen, Denmark; 

Phrase: "Idiotype vaccination in multiple myeloma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "a reduction of circulating clonal tumor B cells Thomas Rasmussen,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   739   C0301630:Reduction [Natural Phenomenon or Process]
   739   C0392756:Reduction [Qualitative Concept]
   739   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "Lotta Hansson,"

Phrase: "Anders sterborg,"

Phrase: "Hans Erik Johnsen,"

Phrase: "and"

Phrase: "Hkan Mellstedt From Herlev Hospital,"

Phrase: "University of Copenhagen,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Denmark"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0011318:Denmark [Geographic Area]

Phrase: ";"
Processing 00000000.tx.2: and Departments of Oncology (Radiumhemmet) and Hematology, Karolinska Hospital, Stockholm, Sweden.  

Phrase: "and"

Phrase: "Departments of Oncology"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1704729:Department [Organization]

Phrase: "(Radiumhemmet"

Phrase: ")"

Phrase: "and"

Phrase: "Hematology,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0018943:Haematology NOS [Biomedical Occupation or Discipline]
  1000   C0200627:HEMATOLOGY [Laboratory Procedure]
   928 E C0205488:Haematologic [Functional Concept]

Phrase: "Karolinska Hospital,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   861   C1510665:Hospital [Qualitative Concept]
   777 E C1609061:Hospitals [Intellectual Product]

Phrase: "Stockholm,"

Phrase: "Sweden."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038995:Sweden [Geographic Area]
Processing 00000000.tx.3: Abstract Top Abstract Introduction Study design Results and discussion References  Myeloma cells express the idiotype (Id)specific antigen that may be targeted by Id vaccination. 

Phrase: "Abstract Top Abstract Introduction Study design Results"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   829   C0683954:study results [Finding]
   762   C1274040:Result [Functional Concept]
   762   C1546471:Result [Idea or Concept]
   762   C2825142:Result [Finding]

Phrase: "and"

Phrase: "discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557061:Discussion [Therapeutic or Preventive Procedure]
  1000   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Myeloma cells"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   966   C0333843:Myeloma cell [Cell]
   861   C0007634:Cells [Cell]
   861   C0026764:Myeloma [Neoplastic Process]
   861   C3282337:Cells [Cell]
   861   C3538749:Myeloma [Intellectual Product]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "express"

Phrase: "the idiotype (Id)specific antigen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C0456981:Specific antigen [Immunologic Factor]
   827   C0003320:Antigen [Immunologic Factor]
   727 E C2698667:ANTIGENICITY [Regulation or Law]

Phrase: "that"

Phrase: "may"

Phrase: "be"

Phrase: "targeted by Id vaccination."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0042196:Vaccination [Therapeutic or Preventive Procedure]
   770   C1521840:Targeted [Functional Concept]
   737 E C2986546:TARGET [Diagnostic Procedure]
Processing 00000000.tx.4: Six patients with stage I IgG myeloma were immunized with the autologous purified M component together with the adjuvant cytokines interleukin 12 (IL-12) alone or in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). 

Phrase: "Six patients with stage I IgG myeloma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "immunized with the autologous purified M component"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0030490:M component [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C0439859:Autologous [Qualitative Concept]
   748   C0441923:M+ [Intellectual Product]
   748   C0449432:Component [Manufactured Object]
   748   C1705248:Component [Conceptual Entity]
   748   C1998793:Purified [Functional Concept]

Phrase: "together with the adjuvant cytokines interleukin 12 (IL-12)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "or in combination"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205195:Combination [Qualitative Concept]
   790   C1947911:Combination [Physical Object]

Phrase: "with granulocyte-macrophage colony-stimulating factor (GM-CSF)."
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
  1000   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
  1000   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   937   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   937   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   933   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0018183:granulocyte [Cell]
   804   C0024432:macrophage [Cell]
   804   C0439158:colony [Quantitative Concept]
   804   C1521761:Factor [Functional Concept]
   804   C1947989:Colony [Cell]
   804   C1948023:Stimulating [Natural Phenomenon or Process]
   804   C2827422:Factor [Conceptual Entity]
Processing 00000000.tx.5: The effect of Id vaccination on circulating clonal tumor B cells was monitored by a real-time allele-specific oligonucleotide polymerase chain reaction method. 

Phrase: "The effect of Id vaccination"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "on circulating clonal tumor B cells"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   902   C0027625:Circulating Tumor Cells [Cell]
   902   C3272887:Circulating Tumor Cells [Laboratory Procedure]
   853   C0431085:Tumor cells [Cell]
   840   C0004561:B-Cells [Cell]
   839   C0009013:Clone Cells [Cell]
   836 E C0597032:Tumor Cell [Cell]
   804   C0007634:Cells [Cell]
   804   C3282337:Cells [Cell]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]

Phrase: "was"

Phrase: "monitored"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   966   C0030695:monitor [Health Care Activity]
   966   C0150369:monitor [Health Care Activity]
   966   C0181904:Monitor [Medical Device]
   966   C0596972:Monitor [Medical Device]
   966   C1521743:Monitor [Professional or Occupational Group]
   966   C1704646:Monitor [Manufactured Object]

Phrase: "by a real-time allele-specific oligonucleotide polymerase chain reaction method."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   791   C0025663:Method [Intellectual Product]
   791   C0449851:Method [Functional Concept]
   791   C0871511:METHOD [Intellectual Product]
   727   C1709846:Real-Time Polymerase Chain Reaction [Molecular Biology Research Technique]
   700   C0034746:time reaction [Temporal Concept]
Processing 00000000.tx.6: No other treatment was given. 

Phrase: "No"

Phrase: "other treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "was"

Phrase: "given."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]
Processing 00000000.tx.7: Reduction of blood tumor mass was observed in 4 of 6 patients, with one patient achieving a complete molecular remission in blood. 

Phrase: "Reduction of blood tumor mass"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0301630:Reduction [Natural Phenomenon or Process]
   760   C0392756:Reduction [Qualitative Concept]
   760   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "observed in 4 of 6 patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0030705:Patients [Patient or Disabled Group]
   753   C1441672:Observed [Functional Concept]

Phrase: "with one patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "achieving"

Phrase: "a complete molecular remission in blood."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C0677874:Complete Remission [Finding]
   753   C0544452:Remission [Finding]
   753   C0687702:remission [Neoplastic Process]
Processing 00000000.tx.8: In 3 of these 4 patients an Id-specific T-cell response was induced. 

Phrase: "In 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "of these 4 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "an Id-specific T-cell response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0871261:Response [Organism Attribute]
   804   C1704632:Response [Finding]
   804   C1706817:Response [Intellectual Product]
   804   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "induced."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]
Processing 00000000.tx.9: In the remaining 2 patients with an unchanged level of blood tumor cells, one patient mounted a T-cell response, whereas the other did not. 

Phrase: "In the remaining 2 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "with an unchanged level"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0441889:Level [Qualitative Concept]
   861   C0456079:Level [Classification]
   861   C1547707:Level [Geographic Area]
   861   C2946261:Level [Pharmacologic Substance]

Phrase: "of blood tumor cells,"
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   913   C0005773:Blood Cells [Cell]
   901   C0431085:Tumor cells [Cell]
   869 E C2328697:Hemal cell [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "one patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "mounted"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0449878:mounted [Finding]
   966 E C0181909:Mount [Medical Device]

Phrase: "a T-cell response,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0871261:Response [Organism Attribute]
   812   C1704632:Response [Finding]
   812   C1706817:Response [Intellectual Product]
   812   C2911692:Response [Mental Process]

Phrase: "whereas"

Phrase: "the other"

Phrase: "did"

Phrase: "not."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]
Processing 00000000.tx.10: No significant change in the serum M protein level was noted. 

Phrase: "No significant change in the serum M protein level"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   762   C0442739:No change [Finding]
   762   C1548568:No change [Intellectual Product]
   742   C0392747:Change [Functional Concept]
   742   C0443172:change [Quantitative Concept]
   742   C1705241:Change [Quantitative Concept]

Phrase: "was"

Phrase: "noted."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]
Processing 00000000.tx.11: Id vaccination may target clonal B cells, suggesting that this strategy might be conducive to achieving tumor control. 

Phrase: "Id vaccination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "may"

Phrase: "target"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1521840:Target [Functional Concept]
  1000   C2986546:TARGET [Diagnostic Procedure]

Phrase: "clonal B cells,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   901   C0004561:B-Cells [Cell]
   877   C0009013:Clone Cells [Cell]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "this strategy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0679199:strategy [Mental Process]

Phrase: "might"

Phrase: "be"

Phrase: "conducive to achieving tumor control."
Processing 00000000.tx.12: The clinical significance of these findings remains to be established.  

Phrase: "The clinical significance of these findings"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C2826293:Clinical Significance [Finding]
   753   C0237881:Significance [Quantitative Concept]
   753   C0750502:Significance [Idea or Concept]

Phrase: "remains"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "established."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443211:Established [Qualitative Concept]
  1000   C1272684:Established [Qualitative Concept]
Processing 00000000.tx.13: Introduction Top Abstract Introduction Study design Results and discussion References  Although a high response rate is achieved in patients with multiple myeloma (MM) by high-dose chemotherapy, the management of patients with MM remains a problem. 

Phrase: "Introduction Top Abstract Introduction Study design Results"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   829   C0683954:study results [Finding]
   762   C1274040:Result [Functional Concept]
   762   C1546471:Result [Idea or Concept]
   762   C2825142:Result [Finding]

Phrase: "and"

Phrase: "discussion References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1514811:Reference [Idea or Concept]
   827   C1706462:Reference [Conceptual Entity]

Phrase: "Although"

Phrase: "a high response rate"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   901   C0237629:Response Rate [Temporal Concept]
   827   C0871208:Rate [Activity]
   827   C0871261:Response [Organism Attribute]
   827   C1521828:Rate [Quantitative Concept]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "is"

Phrase: "achieved in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0030705:Patients [Patient or Disabled Group]

Phrase: "with multiple myeloma (MM)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "by high-dose chemotherapy,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]

Phrase: "the management of patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0001554:Management [Occupational Activity]
   770   C0376636:management [Health Care Activity]
   770   C1273870:Management [Occupational Activity]
   770   C3273539:Management [Occupation or Discipline]

Phrase: "with MM"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "remains"

Phrase: "a problem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033213:Problem [Finding]
Processing 00000000.tx.14: Complementary therapeutics are needed to cure or control the disease. 

Phrase: "Complementary therapeutics"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0039796:Therapeutics [Therapeutic or Preventive Procedure]
   861   C0723712:therapeutics [Organic Chemical,Pharmacologic Substance]

Phrase: "are"

Phrase: "needed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Needed [Qualitative Concept]
  1000   C0686904:needed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "cure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1880198:Cure [Conceptual Entity]

Phrase: "or"

Phrase: "control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "the disease."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.15: The idiotype (Id) of the myeloma immunoglobulin (Ig) is regarded as a tumor-specific antigen and a target for immunotherapy. 

Phrase: "The idiotype"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "(Id"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ")"

Phrase: "of the myeloma immunoglobulin (Ig)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C1621846:immunoglobulin [Molecular Function]

Phrase: "is"

Phrase: "regarded as a tumor-specific antigen"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   833   C0041361:tumor-specific antigen [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Tumor antigen
   790   C0456981:Specific antigen [Immunologic Factor]
   753   C0003320:Antigen [Immunologic Factor]
   753   C0027651:Tumor [Neoplastic Process]
   753   C0205369:Specific [Qualitative Concept]
   753   C1552740:specific [Intellectual Product]
   753   C1578706:Tumor [Intellectual Product]
   753   C3273930:Tumor [Finding]

Phrase: "and"

Phrase: "a target for immunotherapy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1521840:Target [Functional Concept]
   770   C2986546:TARGET [Diagnostic Procedure]
Processing 00000000.tx.16: Naturally occurring major histocompatibility complex (MHC)restricted myeloma Id-specific T cells have been identified.1 Such T cells may target Id Ig peptide/MHC complexes on myeloma cells and might lyse tumor cells.2,3 Id vaccination may therefore be a treatment approach to induce a therapeutic Id-specific T-cell response.2, 3, 4 The concept of Id immunization in MM was introduced about 30 years ago.5 The Id seems, however, to be a weak immunogen; 

Phrase: "Naturally"

Phrase: "occurring"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1709305:Occur [Activity]
   966   C2745955:OCCUR [Temporal Concept]

Phrase: "major histocompatibility complex (MHC)restricted myeloma Id-specific T cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   825   C0333843:Myeloma cell [Cell]
   807   C0039194:T-Cells [Cell]
   791   C0007634:Cells [Cell]
   791   C3282337:Cells [Cell]
   758 E C1269647:Cell [Cell]
   758 E C1704653:Cell [Medical Device]
   758 E C1948049:Cell [Spatial Concept]

Phrase: "have"

Phrase: "been"

Phrase: "identified.1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205396:Identified [Qualitative Concept]
   861   C1550043:Identified [Finding]
   861   C1551388:Identified [Functional Concept]

Phrase: "Such T cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0039194:T-Cells [Cell]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "may"

Phrase: "target"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1521840:Target [Functional Concept]
  1000   C2986546:TARGET [Diagnostic Procedure]

Phrase: "Id Ig peptide/MHC complexes on myeloma cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1704241:Complexes [Chemical Viewed Structurally]

Phrase: "and"

Phrase: "might"

Phrase: "lyse"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024348:lyse [Pathologic Function]

Phrase: "tumor cells.2,"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   901   C0431085:Tumor cells [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "3 Id vaccination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "may"

Phrase: "therefore"

Phrase: "be"

Phrase: "a treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "approach"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449445:Approach [Spatial Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "a therapeutic Id-specific T-cell response.2,"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   877   C0521982:Therapeutic response [Clinical Attribute]
   818   C0039194:T-cell [Cell]
   795   C0007634:Cell [Cell]
   795   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
   795   C0039796:Therapeutic [Therapeutic or Preventive Procedure]
   795   C0205369:Specific [Qualitative Concept]
   795   C0302350:Therapeutic [Functional Concept]
   795   C0871261:Response [Organism Attribute]
   795   C1269647:Cell [Cell]
   795   C1552740:specific [Intellectual Product]
   795   C1704632:Response [Finding]
   795   C1704653:Cell [Medical Device]
   795   C1706817:Response [Intellectual Product]
   795   C1948049:Cell [Spatial Concept]
   795   C2911692:Response [Mental Process]

Phrase: "3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "4"

Phrase: "The concept of Id immunization"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0178566:concept [Idea or Concept]

Phrase: "in MM"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "was"

Phrase: "introduced about 30 years ago.5"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0439234:years [Temporal Concept]
   719 E C0439508:/year [Temporal Concept]
   719   C1292748:introduce [Functional Concept]

Phrase: "The Id"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "seems"

Phrase: ","

Phrase: "however,"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "a weak immunogen"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0003320:Immunogen [Immunologic Factor]
   789 E C0872192:immunogenic [Functional Concept]

Phrase: ";"
Processing 00000000.tx.17: to evoke a strong response, adjuvant cytokines should be added. 

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "evoke"

Phrase: "a strong response,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "adjuvant cytokines"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0079189:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1524094:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "should"

Phrase: "be"

Phrase: "added."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1524062:Added [Functional Concept]
   966 E C1883712:Add [Functional Concept]
Processing 00000000.tx.18: Granulocyte-macrophage colony-stimulating factor (GM-CSF) augments the functional capacity of antigen-presenting cells and interleukin 12 (IL-12) amplifies the immune response and leads to a type 1 T-cell response.4 A TH1-type cellular response seems to be of importance for tumor regression, whereas a TH2 T-cell response might provide a microenvironment conducive to disease progression.6 Id vaccination in malignant lymphomas induced Id-specific T cells and complete blood molecular remission.7 In MM, Id vaccination evoked an Id-specific T-cell response and occasionally clinical effects such as reduction of serum M component and disease stabilization.8 The clonal cell compartment in myeloma represents an ongoing differentiating cell population9 including preswitch cells.10,11 The number of preplasma cells seems to be related to disease burden and clinical outcome.12 Clonal preplasma cells express MHC class I and II molecules and plasma cells, mainly MHC class I molecules with Id Ig peptides in the groove and may thus be targeted by Id-specific T cells. 

Phrase: "Granulocyte-macrophage colony-stimulating factor"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
  1000   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
  1000   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   937   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   937   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   933   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0018183:granulocyte [Cell]
   804   C0024432:macrophage [Cell]
   804   C0439158:colony [Quantitative Concept]
   804   C1521761:Factor [Functional Concept]
   804   C1947989:Colony [Cell]
   804   C1948023:Stimulating [Natural Phenomenon or Process]
   804   C2827422:Factor [Conceptual Entity]

Phrase: "(GM-CSF"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
  1000   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
  1000   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   937   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   937   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   933   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0018183:granulocyte [Cell]
   804   C0024432:macrophage [Cell]
   804   C0439158:colony [Quantitative Concept]
   804   C1521761:Factor [Functional Concept]
   804   C1947989:Colony [Cell]
   804   C1948023:Stimulating [Natural Phenomenon or Process]
   804   C2827422:Factor [Conceptual Entity]

Phrase: ")"

Phrase: "augments"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205217:augment [Quantitative Concept]

Phrase: "the functional capacity of antigen-presenting cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0695468:functional capacity [Therapeutic or Preventive Procedure]
   778   C1998319:Functional capacity [Finding]
   748   C1516240:Capacity [Quantitative Concept]

Phrase: "and"

Phrase: "interleukin 12"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "(IL-12"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: ")"

Phrase: "amplifies"

Phrase: "the immune response"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0301872:Immune response [Organ or Tissue Function]
   861   C0439662:Immune [Functional Concept]
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "leads to a type 1 T-cell response.4"
Meta Candidates (Total=22; Excluded=0; Pruned=0; Remaining=22)
   764   C0039194:T-cell [Cell]
   764   C0441729:Type 1 [Classification]
   762   C0007634:Cell Type [Cell]
           Cell
   762   C0441732:Type 4 [Classification]
   762   C0449475:cell type [Intellectual Product]
   762   C2346662:Lead 4+ [Element, Ion, or Isotope]
   742   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   742   C0181586:leads [Medical Device]
   742   C0332307:Type [Qualitative Concept]
   742   C0871261:Response [Organism Attribute]
   742   C1269647:Cell [Cell]
   742   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   742   C1522538:Lead [Functional Concept]
   742   C1547052:*Type [Quantitative Concept]
   742   C1704632:Response [Finding]
   742   C1704653:Cell [Medical Device]
   742   C1706817:Response [Intellectual Product]
   742   C1948049:Cell [Spatial Concept]
   742   C2348269:Lead [Element, Ion, or Isotope]
   742   C2911692:Response [Mental Process]
   742   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "A TH1-type cellular response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0871261:Response [Organism Attribute]
   812   C1704632:Response [Finding]
   812   C1706817:Response [Intellectual Product]
   812   C2911692:Response [Mental Process]

Phrase: "seems"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be of importance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2987476:Be [Conceptual Entity]

Phrase: "for tumor regression,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1718423:Tumor regression [Organism Attribute]
   861   C0684320:Regression [Pathologic Function]
   861   C0684321:Regression [Mental Process]

Phrase: "whereas"

Phrase: "a TH2 T-cell response"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   812   C0871261:Response [Organism Attribute]
   812   C1704632:Response [Finding]
   812   C1706817:Response [Intellectual Product]
   812   C2911692:Response [Mental Process]
   708   C0242633:Th 2 cell [Cell]

Phrase: "might"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "a microenvironment"

Phrase: "conducive to disease progression.6 Id vaccination"

Phrase: "in malignant lymphomas"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0024299:Malignant Lymphomas [Neoplastic Process]
           Lymphomas
   861   C0205282:Malignant [Qualitative Concept]
   861   C0334590:MALIGNANT [Neoplastic Process]
   861   C1533592:MALIGNANT [Neoplastic Process]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "Id-specific T cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0039194:T-Cells [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "complete blood molecular remission.7 In MM,"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   815   C0153869:Multiple myeloma in remission [Neoplastic Process]
   770   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   767   C0677874:Complete Remission [Finding]
   744   C0005767:Blood [Tissue]
   744   C0005768:blood [Body Substance]
   744   C0205197:Complete [Qualitative Concept]
   744   C0229664:Blood [Body Substance]
   744   C0439064:Multiple [Quantitative Concept]
   744   C0544452:Remission [Finding]
   744   C0687702:remission [Neoplastic Process]
   744   C0725685:COMPLEAT [Food]
   744   C1521991:Molecular [Qualitative Concept]
   744   C3538749:Myeloma [Intellectual Product]

Phrase: "Id vaccination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "evoked"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444748:Evoked [Qualitative Concept]

Phrase: "an Id-specific T-cell response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0871261:Response [Organism Attribute]
   804   C1704632:Response [Finding]
   804   C1706817:Response [Intellectual Product]
   804   C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "occasionally clinical effects such as reduction of serum M component"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   739   C1280500:effects [Qualitative Concept]
   706 E C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "disease stabilization.8"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0012634:Disease [Disease or Syndrome]
   827   C1293130:Stabilisation [Therapeutic or Preventive Procedure]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "The clonal cell compartment in myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1948049:Cell (compartment) [Spatial Concept]
   790   C2349967:Cell compartment [Anatomical Structure]
   753   C1185625:Compartment [Body Space or Junction]
   753   C2986730:Compartment [Spatial Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "an ongoing differentiating cell population9"

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "preswitch cells.10,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "11"

Phrase: "The number of preplasma cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   781   C0007584:Cell Number [Laboratory Procedure]
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "seems"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "related to disease burden"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   770   C0012634:Disease [Disease or Syndrome]
   770   C0439849:Related [Qualitative Concept]
   770   C0445223:Related [Finding]
   770   C2828008:Burden [Idea or Concept]
   737 E C0163712:Relate [Organic Chemical]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "clinical outcome.12 Clonal preplasma cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   803   C0009013:Clone Cells [Cell]
   799   C0007634:Cells [Cell]
   799   C3282337:Cells [Cell]
   766 E C1269647:Cell [Cell]
   766 E C1704653:Cell [Medical Device]
   766 E C1948049:Cell [Spatial Concept]

Phrase: "express"

Phrase: "MHC class I"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   884   C0024518:Major Histocompatibility Complex [Gene or Genome]
   884   C1753349:Major histocompatibility complex [Cell Component]
   853   C2245017:Complex I [Cell Component]
   840   C0441885:Class I [Classification]
   840   C2698967:Class I [Finding]
   804   C0019627:Histocompatibility [Qualitative Concept]
   804   C0021966:I- [Inorganic Chemical]
   804   C0205164:Major [Qualitative Concept]
   804   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0439855:Complex [Qualitative Concept]
   804   C0456387:Class [Intellectual Product]
   804   C1704241:Complex [Chemical Viewed Structurally]
   804   C1705943:Class [Classification]

Phrase: "and"

Phrase: "II molecules"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0567416:molecules [Substance]
   777 E C1521991:Molecular [Qualitative Concept]

Phrase: "and"

Phrase: "plasma cells,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C0032112:Plasma Cells [Cell]
   861   C0007634:Cells [Cell]
   861   C0032105:Plasma [Body Substance]
   861   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "mainly MHC class I molecules with Id Ig peptides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0567416:molecules [Substance]

Phrase: "in the groove"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1184482:Groove [Body Space or Junction]

Phrase: "and"

Phrase: "may"

Phrase: "thus"

Phrase: "be"

Phrase: "targeted by Id-specific T cells."
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
   790   C0039194:T-Cells [Cell]
   767   C0221284:Target cells [Cell]
   767   C3272919:Target Cells [Laboratory Procedure]
   753   C0007634:Cells [Cell]
   753   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0205369:Specific [Qualitative Concept]
   753   C1521840:Targeted [Functional Concept]
   753   C1552740:specific [Intellectual Product]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]
   719 E C2986546:TARGET [Diagnostic Procedure]
Processing 00000000.tx.19: In this study, we monitored peripheral blood (PB) tumor cells by a real-time allele-specific oligonucleotide (ASO) polymerase chain reaction (PCR) method in MM patients undergoing Id vaccination and could show that immunization, using the autologous myeloma Id, induced reduction in PB tumor mass.  

Phrase: "In this study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "we"

Phrase: "monitored"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   966   C0030695:monitor [Health Care Activity]
   966   C0150369:monitor [Health Care Activity]
   966   C0181904:Monitor [Medical Device]
   966   C0596972:Monitor [Medical Device]
   966   C1521743:Monitor [Professional or Occupational Group]
   966   C1704646:Monitor [Manufactured Object]

Phrase: "peripheral blood (PB) tumor cells"
Meta Candidates (Total=15; Excluded=5; Pruned=0; Remaining=10)
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0431085:Tumor cells [Cell]
   830 E C2328697:Hemal cell [Cell]
   827 E C0597032:Tumor Cell [Cell]
   819   C0027668:Tumor, Blood Vessel [Neoplastic Process]
   819   C0282607:Blood vessel tumor [Neoplastic Process]
   812   C0007634:Cells [Cell]
   812   C0027651:Tumor [Neoplastic Process]
   812   C1578706:Tumor [Intellectual Product]
   812   C3273930:Tumor [Finding]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: "by a real-time allele-specific oligonucleotide (ASO) polymerase chain reaction (PCR) method"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   791   C0025663:Method [Intellectual Product]
   791   C0449851:Method [Functional Concept]
   791   C0871511:METHOD [Intellectual Product]
   727   C1709846:Real-Time Polymerase Chain Reaction [Molecular Biology Research Technique]
   700   C0034746:time reaction [Temporal Concept]

Phrase: "in MM patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0026764:Multiple Myeloma [Neoplastic Process]

Phrase: "undergoing"

Phrase: "Id vaccination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "could"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "that immunization,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0020971:Immunisation [Therapeutic or Preventive Procedure]
  1000   C0042196:immunisation [Therapeutic or Preventive Procedure]
  1000   C3244291:immunization [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the autologous myeloma Id,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "induced reduction in PB tumor mass."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0301630:Reduction [Natural Phenomenon or Process]
   748   C0392756:Reduction [Qualitative Concept]
   748   C0441610:Reduction [Therapeutic or Preventive Procedure]
Processing 00000000.tx.20: Study design Top Abstract Introduction Study design Results and discussion References  Patients with MM stage I and an increased serum M-component concentration were included. 

Phrase: "Study design Top Abstract Introduction Study design Results"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   892   C0683954:study results [Finding]
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]

Phrase: "and"

Phrase: "discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557061:Discussion [Therapeutic or Preventive Procedure]
  1000   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Patients with MM stage I"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0030705:Patients [Patient or Disabled Group]
   716   C0278722:Multiple Myeloma Stage I [Neoplastic Process]
   716   C2346458:Multiple Myeloma Stage I [Neoplastic Process]

Phrase: "and"

Phrase: "an increased serum M-component concentration"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   875   C0683149:serum concentration [Quantitative Concept]
   804   C0086045:Concentration [Mental Process]
   804   C1446561:Concentration [Quantitative Concept]
   733 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "were"

Phrase: "included."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0332257:included [Functional Concept]
  1000   C3538986:INCLUDED [Gene or Genome]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]
Processing 00000000.tx.21: Ten patients were considered for the study. 

Phrase: "Ten patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "considered for the study."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0557651:Study [Manufactured Object]
   770   C0750591:considered [Idea or Concept]
   770   C2603343:Study [Research Activity]
Processing 00000000.tx.22: In 6 of 10 patients we were able to monitor the level of clonal cells using complementarity-determining region 3 (CDR3)specific PCR assays; 

Phrase: "In 6"

Phrase: "of 10 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "we"

Phrase: "were"

Phrase: "able to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0085732:Able [Organism Attribute]
   861   C1299581:Able [Finding]

Phrase: "monitor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0030695:monitor [Health Care Activity]
  1000   C0150369:monitor [Health Care Activity]
  1000   C0181904:Monitor [Medical Device]
  1000   C0596972:Monitor [Medical Device]
  1000   C1521743:Monitor [Professional or Occupational Group]
  1000   C1704646:Monitor [Manufactured Object]

Phrase: "the level"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0441889:Level [Qualitative Concept]
  1000   C0456079:Level [Classification]
  1000   C1547707:Level [Geographic Area]
  1000   C2946261:Level [Pharmacologic Substance]

Phrase: "of clonal cells using complementarity-determining region 3 (CDR3)specific PCR assays"
Meta Candidates (Total=33; Excluded=10; Pruned=0; Remaining=23)
   822   C0887928:Complementarity Determining Region 3 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   809   C0021024:Complementarity-Determining Region [Amino Acid, Peptide, or Protein,Immunologic Factor]
   809   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   805   C1268228:Cell region [Cell Component]
   786   C0007634:Cells [Cell]
   786   C0017446:Region [Geographic Area]
   786   C0205147:Region [Spatial Concept]
   786   C0205369:Specific [Qualitative Concept]
   786   C0332285:Of [Spatial Concept]
   786   C0337112:Chain [Manufactured Object]
   786   C0443286:Reaction [Functional Concept]
   786   C1114821:Reaction [Clinical Attribute]
   786   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   786   C1522642:Clonal [Tissue]
   786   C1524063:Using [Functional Concept]
   786   C1524075:Chain [Idea or Concept]
   786   C1552740:specific [Intellectual Product]
   786   C1704387:Clonal [Qualitative Concept]
   786   C3282337:Cells [Cell]
   761   C0009013:Clone Cells [Cell]
       E   Clone
   753   C0005507:Assay [Laboratory Procedure]
   753 E C0042153:use [Functional Concept]
   753   C0243073:assay [Qualitative Concept]
   753 E C0457083:Use [Functional Concept]
   753 E C1269647:Cell [Cell]
   753   C1510438:Assay [Laboratory Procedure]
   753 E C1704653:Cell [Medical Device]
   753 E C1947944:Use [Intellectual Product]
   753 E C1948049:Cell [Spatial Concept]
   715 E C0205276:Regional [Spatial Concept]
   715 E C0796368:clonality [Diagnostic Procedure]
   715 E C1947913:Regional [Spatial Concept]

Phrase: ";"
Processing 00000000.tx.23: results from these 6 patients are included in this report. 

Phrase: "results from these 6 patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C1274040:Result [Functional Concept]
   726   C1546471:Result [Idea or Concept]
   726   C2825142:Result [Finding]

Phrase: "are"

Phrase: "included in this report."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   770   C0332257:included [Functional Concept]
   770   C0684224:Report [Intellectual Product]
   770   C0700287:Report [Health Care Activity]
   770   C3273238:Report [Intellectual Product]
   770   C3538986:INCLUDED [Gene or Genome]
   737 E C1552866:include [Idea or Concept]
   737 E C2700399:Include [Activity]
Processing 00000000.tx.24: The study was approved by the Ethical Committee of the Karolinska Institute. 

Phrase: "The study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "was"

Phrase: "approved by the Ethical Committee of the Karolinska Institute."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   742   C0021622:institute [Organization]
   742   C0026531:ethical [Idea or Concept]
   742   C0205540:Approved [Qualitative Concept]
   742   C1272753:Institute [Idea or Concept]
   742   C2699414:Committee [Group]
Processing 00000000.tx.25: The M component was purified as described.4 The patients were immunized with the autologous Id together with IL-12 with or without GM-CSF as follows: (1) In the IL-12/GM-CSF group, 0.5 mg of the autologous M component in 0.5% aluminum phosphate (SBL-Vaccin, Solna, Sweden) was given intracutaneously on day 1 together with 75 g/d GM-CSF (Leucomax; Schering-Plough, Kenilworth, NJ) intracutaneously at the same site, days 1 to 4, and 30 ng/kg IL-12 subcutaneously day 1 (Wyeth, London, United Kingdom). 

Phrase: "The M component"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0030490:M component [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]
   861   C0449432:Component [Manufactured Object]
   861   C1705248:Component [Conceptual Entity]

Phrase: "was"

Phrase: "purified"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1998793:Purified [Functional Concept]
   907 E C1947930:Cleanse [Activity]

Phrase: "as"

Phrase: "described.4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552738:described [Idea or Concept]

Phrase: "The patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "immunized with the autologous Id"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0439859:Autologous [Qualitative Concept]

Phrase: "together with IL-12"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "with"

Phrase: "or without GM-CSF"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   897   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
   897   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   897   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
   897   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   853   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   853   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   840   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   814   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0018183:granulocyte [Cell]
   748   C0024432:macrophage [Cell]
   748   C0439158:colony [Quantitative Concept]
   748   C1521761:Factor [Functional Concept]
   748   C1947989:Colony [Cell]
   748   C1948023:Stimulating [Natural Phenomenon or Process]
   748   C2827422:Factor [Conceptual Entity]

Phrase: "as"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")"

Phrase: "In the IL-12/GM-CSF group,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   793   C0441833:Group [Idea or Concept]
   793   C0687744:group [Population Group]
   793   C1257890:Group [Population Group]
   793   C1552516:Group [Health Care Related Organization]
   793   C1705428:Group [Conceptual Entity]
   793   C1705429:Group [Population Group]
   723   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   723   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   723   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
   723   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]

Phrase: "0.5 mg of the autologous M component"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0439269:mg% [Quantitative Concept]
   744   C1960952:mg % [Quantitative Concept]
   744   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "in 0.5% aluminum phosphate"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0051519:Aluminium phosphate [Inorganic Chemical,Pharmacologic Substance]
   812   C0002367:Aluminium [Element, Ion, or Isotope]
   812   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   812   C0031701:phosphate [Organophosphorus Compound]
   812   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]
   812   C2348254:ALUMINUM [Element, Ion, or Isotope]

Phrase: "(SBL-Vaccin,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0042196:VACCIN [Therapeutic or Preventive Procedure]
   861   C0077967:vaccin [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Solna,"

Phrase: "Sweden"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038995:Sweden [Geographic Area]

Phrase: ")"

Phrase: "was"

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "intracutaneously on day 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0332173:/day [Temporal Concept]
   770   C0439228:day [Temporal Concept]
   770   C0439505:/day [Temporal Concept]

Phrase: "together with 75 g/d GM-CSF"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   890   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
   890   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   890   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
   890   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   864   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   835   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   793   C0018183:granulocyte [Cell]
   793   C0024432:macrophage [Cell]
   793   C0439158:colony [Quantitative Concept]
   793   C1521761:Factor [Functional Concept]
   793   C1947989:Colony [Cell]
   793   C1948023:Stimulating [Natural Phenomenon or Process]
   793   C2827422:Factor [Conceptual Entity]

Phrase: "(Leucomax"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0699995:Leucomax [Organic Chemical,Pharmacologic Substance]

Phrase: "; Schering-Plough,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0331973:Schering-Plough [Health Care Related Organization]

Phrase: "Kenilworth,"

Phrase: "NJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0027971:NJ [Geographic Area]

Phrase: ")"

Phrase: "intracutaneously at the same site,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0205145:Site [Spatial Concept]
   760   C0445247:Same [Qualitative Concept]
   760   C1515974:Site [Body Location or Region]
   760   C2825164:Site [Spatial Concept]

Phrase: "days 1 to 4,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   770   C0439228:days [Temporal Concept]
   737 E C0332173:/day [Temporal Concept]
   737 E C0439505:/day [Temporal Concept]

Phrase: "and"

Phrase: "30 ng/kg IL-12 subcutaneously day 1"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   878   C0964553:NG.1 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   878   C1334110:NG.1 [Gene or Genome]
   869   C1827144:ng/kg/day [Quantitative Concept]
   864   C1636666:ng/day [Quantitative Concept]
   850   C0021755:Interleukin-1 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   850   C0439418:kg/day [Quantitative Concept]
   850   C1522428:Interleukin 1 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   812   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   812   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C1638318:ng/kg [Quantitative Concept]
   793   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   793   C0022718:KG [Geographic Area]
   793   C0332173:/day [Temporal Concept]
   793   C0439209:kg [Quantitative Concept]
   793   C0439228:day [Temporal Concept]
   793   C0439505:/day [Temporal Concept]
   793   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "(Wyeth,"

Phrase: "London,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023973:London [Geographic Area]

Phrase: "United Kingdom"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0041700:United Kingdom [Geographic Area]
   861   C1708611:Kingdom [Classification]
   827   C0166872:unite [Biomedical or Dental Material]

Phrase: ")."
Processing 00000000.tx.26: (2) In the IL-12 group, 0.5 mg of the M component was given intracutaneously on day 1 and 30 ng/kg IL-12 subcutaneously on day 1. 

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "In the IL-12 group,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1552516:Group [Health Care Related Organization]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   734   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   734   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "0.5 mg of the M component"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0439269:mg% [Quantitative Concept]
   748   C1960952:mg % [Quantitative Concept]
   748   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "was"

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "intracutaneously on day 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0332173:/day [Temporal Concept]
   770   C0439228:day [Temporal Concept]
   770   C0439505:/day [Temporal Concept]

Phrase: "and"

Phrase: "30 ng/kg IL-12 subcutaneously on day 1."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   764   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   764   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   762   C0021755:Interleukin-1 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   762   C1426048:INTERLEUKIN 30 [Gene or Genome]
   762   C1522428:Interleukin 1 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   762   C2697780:Interleukin 30 [Laboratory Procedure]
   742   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   742   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.27: Immunizations were done at weeks 0, 2, 4, 6, 8, 14, and 30. 

Phrase: "Immunizations"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0020971:Immunizations [Therapeutic or Preventive Procedure]
   966 E C0042196:immunization [Therapeutic or Preventive Procedure]
   966 E C3244291:immunization [Functional Concept]

Phrase: "were"

Phrase: "done at weeks 0,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0439230:weeks [Temporal Concept]
   770   C1272695:Done [Qualitative Concept]
   770   C2746065:Done [Temporal Concept]
   737 E C0332174:/week [Temporal Concept]

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "4,"

Phrase: "6,"

Phrase: "8,"

Phrase: "14,"

Phrase: "and"

Phrase: "30."
Processing 00000000.tx.28: Two methods were applied to detect Id-specific T cells: a proliferation assay (3H-thymidine incorporation) and ELISPOT (interferon- [IFN-]). 

Phrase: "Two methods"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0025663:Methods [Intellectual Product]
   861   C0025664:methods [Intellectual Product]
   861   C0449851:Methods [Functional Concept]
   827 E C0871511:METHOD [Intellectual Product]

Phrase: "were"

Phrase: "applied"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0185125:Applied [Health Care Activity]
   966 E C1632850:Apply [Functional Concept]
   966 E C1879355:Apply [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "detect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442726:detect [Finding]

Phrase: "Id-specific T cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0039194:T-Cells [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: ":"

Phrase: "a proliferation assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0005507:Assay [Laboratory Procedure]
   861   C0243073:assay [Qualitative Concept]
   861   C1510438:Assay [Laboratory Procedure]

Phrase: "(3H-thymidine incorporation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0243126:incorporation [Functional Concept]

Phrase: ")"

Phrase: "and"

Phrase: "ELISPOT (interferon-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.29: The techniques have been described in detail elsewhere.4 Briefly, for the proliferation assay peripheral blood mononuclear cells (PBMCs) were stimulated with purified F(ab')2 fragments of the autologous monoclonal IgG (1 pg/mL to 100 g/mL) as well as with 3 allogeneic monoclonal isotype-matched IgGs from other myeloma patients and cultured for 6 days. 

Phrase: "The techniques"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0025664:techniques [Intellectual Product]
  1000   C0449851:Techniques [Functional Concept]

Phrase: "have"

Phrase: "been"

Phrase: "described in detail elsewhere.4 Briefly,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1522508:Detail [Qualitative Concept]
   753   C1552738:described [Idea or Concept]
   753   C1561567:detail [Functional Concept]

Phrase: "for the proliferation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0334094:Proliferation [Pathologic Function]
  1000   C1514485:Proliferation [Functional Concept]

Phrase: "assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]

Phrase: "peripheral blood mononuclear cells (PBMCs)"
Meta Candidates (Total=24; Excluded=12; Pruned=0; Remaining=12)
  1000   C1321301:Peripheral Blood Mononuclear Cells [Cell]
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0229664:peripheral blood [Body Substance]
           Blood
   861   C0806987:Mononuclear cells [Cell]
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C1513475:Mononuclear [Clinical Attribute]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "were"

Phrase: "stimulated with purified F(ab')2 fragments"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   748   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   748   C0332255:fragments [Functional Concept]
   748   C0439133:(f) [Intellectual Product]
   748   C0486805:Fragments [Body Substance]
   748   C1553038:[f] [Quantitative Concept]
   748   C1948023:Stimulated [Natural Phenomenon or Process]
   748   C1998793:Purified [Functional Concept]
   714 E C1708096:Fragment [Qualitative Concept]

Phrase: "of the autologous monoclonal IgG (1 pg/mL"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439297:pg/mL [Quantitative Concept]
   799   C0439526:/mL [Quantitative Concept]

Phrase: "to 100 g/"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "mL)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439526:/mL [Quantitative Concept]

Phrase: "as well as with 3 allogeneic monoclonal isotype-matched IgGs"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   741   C0946139:IgG.monoclonal [Amino Acid, Peptide, or Protein,Immunologic Factor]
   739   C0021017:Isotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
   739   C0150103:matched [Research Activity]
   739   C0205170:Well [Qualitative Concept]
   739   C0746619:monoclonal [Finding]
   739   C1515895:Allogeneic [Qualitative Concept]
   739   C1708943:Matched [Qualitative Concept]
   739   C3146287:Well [Manufactured Object]

Phrase: "from other myeloma patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "cultured for 6 days."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   770   C0439228:days [Temporal Concept]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737 E C0332173:/day [Temporal Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737 E C0439505:/day [Temporal Concept]
   737   C2242979:Culture [Laboratory Procedure]
Processing 00000000.tx.30: 3H-thymidine was added during the last 18 hours. 

Phrase: "3H-thymidine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040077:Thymidine [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C1442460:3H [Temporal Concept]

Phrase: "was"

Phrase: "added during the last 18 hours."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C1442448:18 Hours [Temporal Concept]
   753   C0439227:hours [Temporal Concept]
   753   C1524062:Added [Functional Concept]
   719 E C0564385:/hour [Quantitative Concept]
   719 E C1883712:Add [Functional Concept]
Processing 00000000.tx.31: Tests were run in triplicate, and mean reactivity was calculated for each triplicate. 

Phrase: "Tests"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0022885:Tests [Laboratory Procedure]
  1000   C0392366:Tests [Intellectual Product]
   966 E C0039593:Test [Functional Concept]

Phrase: "were"

Phrase: "run in triplicate,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205174:Triplicate [Quantitative Concept]
   734   C3274438:RUN-IN [Temporal Concept]

Phrase: "and"

Phrase: "mean reactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   789   C0205332:Reactive [Qualitative Concept]

Phrase: "was"

Phrase: "calculated for each"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0444686:Calculated [Functional Concept]
   790   C1441506:Calculated [Activity]
   790   C1443182:Calculated [Laboratory Procedure]

Phrase: "triplicate."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205174:Triplicate [Quantitative Concept]
Processing 00000000.tx.32: For each testing time, the highest mean value of a triplicate obtained from the 5 different concentrations of the Id was used. 

Phrase: "For each testing time,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   983   C0429928:Test time [Temporal Concept]
   861   C0040223:Time [Temporal Concept]
   861   C3541383:Time [Temporal Concept]
   805 E C0442043:Temporal [Spatial Concept]
   805 E C2362314:Temporal [Temporal Concept]
   777 E C1632851:Times [Quantitative Concept]

Phrase: "the highest mean value of a triplicate"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0444504:Mean [Quantitative Concept]
   748   C1522609:Value [Quantitative Concept]
   748   C2347634:Mean [Quantitative Concept]
   748   C2348143:Mean [Quantitative Concept]

Phrase: "obtained from the 5 different concentrations of the Id"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   742   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
   742   C0086045:Concentrations [Mental Process]
   742   C1301820:Obtained [Functional Concept]
   742   C1705242:Different [Qualitative Concept]
   708 E C1446561:Concentration [Quantitative Concept]
   708 E C1706701:Obtain [Activity]

Phrase: "was"

Phrase: "used."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.33: A stimulation index (SI) was calculated by dividing the mean radioactivity for a triplicate of stimulated cells by that of unstimulated cells. 

Phrase: "A stimulation index (SI)"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0918012:Index [Intellectual Product]
   861   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   861   C1552854:index [Idea or Concept]
   861   C1637833:% index [Quantitative Concept]
   861   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "was"

Phrase: "calculated by dividing"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0332849:dividing [Functional Concept]
   790   C0444686:Calculated [Functional Concept]
   790   C1441506:Calculated [Activity]
   790   C1443182:Calculated [Laboratory Procedure]

Phrase: "the mean radioactivity for a triplicate of stimulated cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0034553:Radioactivity [Natural Phenomenon or Process]

Phrase: "by that"

Phrase: "of unstimulated cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.34: Briefly, for the IFN- ELISPOT, wells of nitrocellulose-bottomed microtiter plates were coated with a mouse monoclonal antihuman IFN- (Mabtech, Stockholm, Sweden) at 4C overnight. 

Phrase: "Briefly,"

Phrase: "for the IFN-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0521125:For [Qualitative Concept]
   827   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "ELISPOT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0920508:ELISPOT [Laboratory Procedure]

Phrase: "wells of nitrocellulose-bottomed microtiter plates"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C0205170:Well [Qualitative Concept]
   719   C3146287:Well [Manufactured Object]

Phrase: "were"

Phrase: "coated with a mouse monoclonal antihuman IFN-"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   748   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0025914:Mouse [Mammal]
   748   C0025929:mouse [Mammal]
   748   C0026809:Mouse [Mammal]
   748   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0746619:monoclonal [Finding]
   748   C1522408:Coated [Qualitative Concept]
   714 E C0453946:Coat [Manufactured Object]
   714 E C2987482:Coat [Body Part, Organ, or Organ Component]

Phrase: "(Mabtech,"

Phrase: "Stockholm,"

Phrase: "Sweden"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038995:Sweden [Geographic Area]

Phrase: ")"

Phrase: "at 4C overnight."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450376:4c [Intellectual Product]
Processing 00000000.tx.35: After removal of the coating solution, the plates were washed twice in phosphate-buffered saline (PBS). 

Phrase: "After removal"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015252:Removal [Therapeutic or Preventive Procedure]
  1000   C0728940:Removal [Therapeutic or Preventive Procedure]

Phrase: "of the coating solution,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037633:Solution [Substance]
   861   C0525069:Solution [Biomedical or Dental Material]

Phrase: "the plates"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1139930:plates [Medical Device]
   966 E C0005971:Plate [Medical Device]
   966 E C3537155:Plate [Manufactured Object]

Phrase: "were"

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: "twice in phosphate-buffered saline (PBS)."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   797   C0991865:buffered phosphate [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   760   C0031701:phosphate [Organophosphorus Compound]
   760   C0036082:Saline [Substance]
   760   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]
   760   C1720725:Twice [Intellectual Product]
   760   C1948050:Twice [Quantitative Concept]
Processing 00000000.tx.36: Subsequently, 100-L aliquots of freshly prepared PBMCs (106 cells/mL) were added to each well. 

Phrase: "Subsequently,"

Phrase: "100-L aliquots of freshly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   726   C1510844:Aliquot [Quantitative Concept]

Phrase: "prepared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1521827:Prepare [Functional Concept]

Phrase: "PBMCs"
Meta Candidates (Total=24; Excluded=12; Pruned=0; Remaining=12)
  1000   C1321301:Peripheral Blood Mononuclear Cells [Cell]
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0229664:peripheral blood [Body Substance]
           Blood
   861   C0806987:Mononuclear cells [Cell]
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C1513475:Mononuclear [Clinical Attribute]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "(106 cells/mL)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C2699156:Cells/mL [Quantitative Concept]
   827   C0439526:/mL [Quantitative Concept]

Phrase: "were"

Phrase: "added to each well."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0205170:Well [Qualitative Concept]
   770   C1524062:Added [Functional Concept]
   770   C3146287:Well [Manufactured Object]
   737 E C1883712:Add [Functional Concept]
Processing 00000000.tx.37: Cells were incubated with F(ab')2 fragments of the autologous or isotypical monoclonal IgG (1 pg/mL to 100 g/mL) for 30 hours. 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "incubated with F(ab')2 fragments of the autologous"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   742   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   742   C0332255:fragments [Functional Concept]
   742   C0439133:(f) [Intellectual Product]
   742   C0439859:Autologous [Qualitative Concept]
   742   C0486805:Fragments [Body Substance]
   742   C1439852:Incubated [Laboratory Procedure]
   742   C1553038:[f] [Quantitative Concept]
   708 E C1708096:Fragment [Qualitative Concept]

Phrase: "or"

Phrase: "isotypical monoclonal IgG (1 pg/mL to 100 g/"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   764   C0439297:pg/mL [Quantitative Concept]
   762   C1300565:g/mL [Quantitative Concept]
   762   C1637390:mL/g [Quantitative Concept]
   742   C0439526:/mL [Quantitative Concept]

Phrase: "mL) for 30 hours."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   802   C0439391:mL/hour [Quantitative Concept]
   770   C0439526:/mL [Quantitative Concept]
Processing 00000000.tx.38: To visualize spots corresponding to single IFN-secreting cells, the cells were washed with PBS and the wells were incubated with a rabbit monoclonal antihuman IFN- at 37C for 2 hours. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "visualize"

Phrase: "spots"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0015230:spots [Disease or Syndrome]
  1000   C0329155:Spot [Fish]
  1000   C0848332:Spots [Sign or Symptom]
  1000   C1427618:SPOT [Gene or Genome]
  1000   C1705203:Spot [Conceptual Entity]

Phrase: "corresponding to single IFN-"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0037179:Single [Population Group]
   770   C0087136:single [Finding]
   770   C0205171:Single [Quantitative Concept]
   770   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "secreting cells,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "the cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "washed with PBS"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   797   C0991865:buffered phosphate [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   760   C0031701:phosphate [Organophosphorus Compound]
   760   C0036082:Saline [Substance]
   760   C1548982:Washed [Idea or Concept]
   760   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]
   726 E C0441648:Wash [Activity]

Phrase: "and"

Phrase: "the wells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205170:Well [Qualitative Concept]
   966   C3146287:Well [Manufactured Object]

Phrase: "were"

Phrase: "incubated with a rabbit monoclonal antihuman IFN-"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0034493:Rabbit [Mammal]
   748   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0746619:monoclonal [Finding]
   748   C1439852:Incubated [Laboratory Procedure]

Phrase: "at 37C"

Phrase: "for 2 hours."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1292425:2 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]
Processing 00000000.tx.39: After washing, biotinylated antirabbit IgG (Vector Lab, Burlingame, CA) was added, followed by avidin-biotin-peroxidase complex (ABC, Vectastin elite kit, Vector Lab) for 50 minutes. 

Phrase: "After washing,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0441648:Washing [Activity]

Phrase: "biotinylated antirabbit IgG"

Phrase: "(Vector Lab,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0022877:Lab [Manufactured Object,Organization]
   805 E C0035100:Rennin [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   777 E C0587081:Labs [Finding]

Phrase: "Burlingame,"

Phrase: "CA)"

Phrase: "was"

Phrase: "added"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1524062:Added [Functional Concept]
   966 E C1883712:Add [Functional Concept]

Phrase: ","

Phrase: "followed by avidin-biotin-peroxidase complex"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   790   C0332283:Followed by [Temporal Concept]
           followed
   753   C0004434:Avidin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0005575:Biotin [Organic Chemical,Pharmacologic Substance,Vitamin]
   753   C0027021:Peroxidase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0031179:Peroxidase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0439855:Complex [Qualitative Concept]
   753   C1318719:Peroxidase [Indicator, Reagent, or Diagnostic Aid]
   753   C1704241:Complex [Chemical Viewed Structurally]
   753   C2700256:Biotin [Laboratory Procedure]
   719 E C1719822:Follow [Intellectual Product]

Phrase: "(ABC,"

Phrase: "Vectastin elite kit,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0812225:KIT [Medical Device]
   827   C1150635:KIT [Molecular Function]
   827   C1705212:Kit [Medical Device]
   827   C1705213:KIT [Medical Device]
   827   C3273202:Kit [Manufactured Object]

Phrase: "Vector Lab) for 50 minutes."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0022877:Lab [Manufactured Object,Organization]
   704 E C0035100:Rennin [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
Processing 00000000.tx.40: After peroxidase staining using the substrate 3-amino-9-ethyl-carbasol (Sigma, St Louis, MO), the number of spots corresponding to cells secreting IFN- was quantified using an automatic device (Zeiss-Kantron, Jena, Germany). 

Phrase: "After peroxidase staining"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0487602:Staining [Laboratory Procedure]
   861   C1704680:Staining [Finding]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the substrate 3-amino-9-ethyl-carbasol"

Phrase: "(Sigma,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: "St Louis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3272372:ST [Intellectual Product]

Phrase: "MO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538743:MO [Idea or Concept]

Phrase: ")"

Phrase: ","

Phrase: "the number of spots"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "corresponding to cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0007634:Cells [Cell]
   790   C3282337:Cells [Cell]
   756 E C1269647:Cell [Cell]
   756 E C1704653:Cell [Medical Device]
   756 E C1948049:Cell [Spatial Concept]

Phrase: "secreting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1327616:Secreting [Cell Function]

Phrase: "IFN-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "quantified"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an automatic device"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025080:Device [Medical Device]
   861   C0699733:Device [Manufactured Object]

Phrase: "(Zeiss-Kantron,"

Phrase: "Jena,"

Phrase: "Germany"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: ")."
Processing 00000000.tx.41: The results are expressed as mean number of spots (cells) of duplicate wells after subtraction of the mean number of spots of unstimulated cells. 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "expressed as mean number of spots"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   753   C0015230:spots [Disease or Syndrome]
   753   C0237753:*Number [Quantitative Concept]
   753   C0329155:Spot [Fish]
   753   C0444504:Mean [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]
   753   C0848332:Spots [Sign or Symptom]
   753   C1427618:SPOT [Gene or Genome]
   753   C1705203:Spot [Conceptual Entity]
   753   C2347634:Mean [Quantitative Concept]
   753   C2348143:Mean [Quantitative Concept]

Phrase: "(cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: ")"

Phrase: "of duplicate wells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205170:Well [Qualitative Concept]
   827   C3146287:Well [Manufactured Object]

Phrase: "after subtraction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2348589:Subtraction [Phenomenon or Process]

Phrase: "of the mean number"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0237753:*Number [Quantitative Concept]
   861   C0444504:Mean [Quantitative Concept]
   861   C0449788:Number [Quantitative Concept]
   861   C2347634:Mean [Quantitative Concept]
   861   C2348143:Mean [Quantitative Concept]

Phrase: "of spots"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0015230:spots [Disease or Syndrome]
  1000   C0329155:Spot [Fish]
  1000   C0848332:Spots [Sign or Symptom]
  1000   C1427618:SPOT [Gene or Genome]
  1000   C1705203:Spot [Conceptual Entity]

Phrase: "of unstimulated cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.42: The highest value obtained by any of the concentration is used. 

Phrase: "The highest value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1522609:Value [Quantitative Concept]

Phrase: "obtained by any of the concentration"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   753   C0086045:Concentration [Mental Process]
   753   C1301820:Obtained [Functional Concept]
   753   C1446561:Concentration [Quantitative Concept]
   719 E C1706701:Obtain [Activity]

Phrase: "is"

Phrase: "used."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.43: A patient was considered to have developed Id-specific T cells if a response was observed at 2 different time points in at least one of the 2 test (read-out) systems. 

Phrase: "A patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "developed Id-specific T cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   840   C0039194:T-Cells [Cell]
   804   C0007634:Cells [Cell]
   804   C3282337:Cells [Cell]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]

Phrase: "if"

Phrase: "a response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: "at 2 different time points in"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   820   C0439547:Points in time [Temporal Concept]
   809 E C1442880:Point in time [Temporal Concept]
   809 E C1552684:Point In Time [Quantitative Concept]
   809 E C2348792:Point in Time [Temporal Concept]
           Time Point
   783   C0808270:Time 2 [Finding]
   753   C0040223:Time [Temporal Concept]
   753   C3541383:Time [Temporal Concept]
   748   C1442103:Time Difference [Temporal Concept]
   748   C1547049:*Time Difference [Quantitative Concept]
   719   C1552961:Point [Quantitative Concept]
   719   C2347617:point [Quantitative Concept]

Phrase: "at least one"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205447:One [Quantitative Concept]

Phrase: "of the 2 test"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0022885:Test [Laboratory Procedure]
   861   C0039593:Test [Functional Concept]
   861   C0392366:test [Intellectual Product]

Phrase: "(read-out"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0034754:Read [Daily or Recreational Activity]
   861   C0439787:Out [Spatial Concept]
   861   C0849355:Out [Qualitative Concept]
   861   C1705179:read [Finding]

Phrase: ")"

Phrase: "systems."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C0449913:System [Functional Concept]
   966   C1553451:System [Manufactured Object]
   966   C1704459:System [Medical Device]
   916 E C0205373:Systemic [Functional Concept]
Processing 00000000.tx.44: To establish a cutoff level for an Id-specific T-cell response, lymphocytes of the myeloma patients were stimulated with purified irrelevant M components. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "establish"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443211:establish [Qualitative Concept]

Phrase: "a cutoff level for an Id-specific T-cell response,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   757   C1547597:Response level [Idea or Concept]
   739   C0441889:Level [Qualitative Concept]
   739   C0456079:Level [Classification]
   739   C1442160:Cutoff [Functional Concept]
   739   C1547707:Level [Geographic Area]
   739   C2946261:Level [Pharmacologic Substance]

Phrase: "lymphocytes of the myeloma patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0024264:Lymphocytes [Cell]

Phrase: "were"

Phrase: "stimulated with purified irrelevant M components."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   790   C0027015:M Components [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756 E C0030490:M component [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0441923:M+ [Intellectual Product]
   753   C0449432:Components [Manufactured Object]
   753   C1948023:Stimulated [Natural Phenomenon or Process]
   753   C1998793:Purified [Functional Concept]
   719 E C1705248:Component [Conceptual Entity]
Processing 00000000.tx.45: An SI of equal to or more than 3.1 (1.21 + 1.88 [mean + 2 SD] of 131 control experiments) was considered a positive response. 

Phrase: "An SI of equal"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0918012:Index [Intellectual Product]
   760   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   760   C1552854:index [Idea or Concept]
   760   C1637833:% index [Quantitative Concept]
   760   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "to"

Phrase: "or"

Phrase: "more than 3.1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205172:More [Functional Concept]

Phrase: "(1.21 + 1.88"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C2827734:1+ [Quantitative Concept]
   812   C2981698:1+ [Classification]

Phrase: "[mean + 2 SD] of 131 control experiments"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   774   C0019737:SD-2 [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ")"

Phrase: "was"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "a positive response."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]
Processing 00000000.tx.46: In the IFN- ELISPOT assay at least 10 cells/105 PBMCs was considered a positive response (1.16 + 7.76 [mean + 2 SD] of 213 control experiments). 

Phrase: "In the IFN-"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0150312:In [Quantitative Concept]
   827   C0332285:In [Spatial Concept]
   827   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "ELISPOT assay at least 10 cells/105 PBMCs"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   796   C0201595:Peripheral blood mononuclear cell assay [Laboratory Procedure]
   738   C0005507:Assay [Laboratory Procedure]
   738   C0243073:assay [Qualitative Concept]
   738   C0920508:ELISPOT [Laboratory Procedure]
   738   C1510438:Assay [Laboratory Procedure]

Phrase: "was"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "a positive response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "(1.16 + 7.76"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   875   C3541329:1-7 [Gene or Genome]
   812   C2827734:1+ [Quantitative Concept]
   812   C2981698:1+ [Classification]

Phrase: "[mean + 2 SD] of 213 control experiments"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   774   C0019737:SD-2 [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ")."
Processing 00000000.tx.47: Both cutoff levels are in line with our previous results.1,4 The patients were tested at weeks 0, 4, 8 or 10, 14, or 16 and 30, respectively. 

Phrase: "Both cutoff levels"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0441889:Levels [Qualitative Concept]
   861   C1442160:Cutoff [Functional Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "are in line with our previous results.1,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   744   C0205132:Line [Spatial Concept]
   744   C0205156:Previous [Temporal Concept]
   744   C1550648:Line [Substance]
   744   C1551058:Are [Quantitative Concept]
   744   C1552607:previous [Temporal Concept]
   744   C1552960:Line [Quantitative Concept]
   711   C1274040:Result [Functional Concept]
   711   C1546471:Result [Idea or Concept]
   711   C2825142:Result [Finding]

Phrase: "4"

Phrase: "The patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "tested at weeks 0,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0392366:tested [Intellectual Product]
   770   C0439230:weeks [Temporal Concept]
   737 E C0022885:Test [Laboratory Procedure]
   737 E C0039593:Test [Functional Concept]
   737 E C0332174:/week [Temporal Concept]

Phrase: "4,"

Phrase: "8"

Phrase: "or"

Phrase: "10,"

Phrase: "14,"

Phrase: "or"

Phrase: "16"

Phrase: "and"

Phrase: "30,"

Phrase: "respectively."
Processing 00000000.tx.48: For the generation of ASO primers and probes, the VH gene sequence was determined by reverse transcriptionPCR (RT-PCR) using consensus VH family primers.13 Patient-specific quantitative real-time PCR analyses were performed as previously described.14 Briefly, real-time PCRs contained a DNA sample, 10 x PCR buffer A (Tris-HCl, pH 8.4, KCl, BSA; 5 L), MgCl2 (optimized for each ASO assay), 200 M each deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate (dGTP), 400 M deoxyuridine triphosphate (dUTP), 1.25 U AmpliTaq gold DNA polymerase, 0.5 U AmpErase uracil N-glycosylase (UNG), and concentration of ASO primer; 

Phrase: "For the generation"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0079411:Generation [Temporal Concept]
  1000   C3146294:Generation [Activity]
   907 E C1414672:Genesis [Gene or Genome]
   907 E C2984892:Genesis [Gene or Genome]

Phrase: "of ASO primers"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0206415:Oligonucleotide Primers [Nucleic Acid, Nucleoside, or Nucleotide]
           Primer

Phrase: "and"

Phrase: "probes,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0182400:Probes [Medical Device]
   966 E C1704681:Probe [Gene or Genome]
   966 E C2347609:Probe [Chemical Viewed Functionally]
   966 E C3536729:Probe [Manufactured Object]

Phrase: "the VH gene sequence"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   827   C0004793:Sequence [Nucleotide Sequence]
   827   C0017337:Gene [Gene or Genome]
   827   C0162326:Sequence [Nucleotide Sequence]
   827   C0162327:Sequence [Nucleotide Sequence]
   827   C1519249:Sequence [Functional Concept]
   755 E C1548958:Sequential [Idea or Concept]
   755 E C1705294:Sequential [Qualitative Concept]

Phrase: "was"

Phrase: "determined by reverse transcriptionPCR (RT-PCR)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1555029:Reverse [Idea or Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "consensus VH family primers.13 Patient-specific quantitative real-time PCR analyses"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   785   C0200931:Polymerase chain reaction analysis [Laboratory Procedure]
   752   C0002778:Analysis [Laboratory Procedure]
   752   C0936012:Analysis [Research Activity]
   752   C1524024:analysis [Functional Concept]

Phrase: "were"

Phrase: "performed as previously"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0884358:Performed [Functional Concept]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "described.14 Briefly,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1552738:described [Idea or Concept]

Phrase: "real-time PCRs"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1709846:Real-Time PCRs [Molecular Biology Research Technique]
   793   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   793   C0677874:pCR [Finding]
   734   C1550177:Real Time [Idea or Concept]

Phrase: "contained"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contained [Functional Concept]
  1000   C2700400:Contained [Activity]

Phrase: "a DNA sample,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]
   734   C0000702:A-DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "10 x PCR buffer A (Tris-HCl,"

Phrase: "pH 8.4,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   913   C2678549:PH-4 [Gene or Genome]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: "KCl,"

Phrase: "BSA"

Phrase: "; 5 L), MgCl2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0024472:MgCl2 [Inorganic Chemical,Pharmacologic Substance]
   734   C2348935:.5 L [Quantitative Concept]

Phrase: "("

Phrase: "optimized for each ASO assay"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0002085:Allele [Gene or Genome]
   748   C0005507:Assay [Laboratory Procedure]
   748   C0028953:Oligonucleotide [Nucleic Acid, Nucleoside, or Nucleotide]
   748   C0205369:Specific [Qualitative Concept]
   748   C0243073:assay [Qualitative Concept]
   748   C1510438:Assay [Laboratory Procedure]
   748   C1552740:specific [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "200 M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "each deoxyadenosine triphosphate (dATP),"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0045186:Deoxy adenosine triphosphate [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0146894:triphosphate [Inorganic Chemical]
   861   C0242246:Deoxyadenosine [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "deoxycytidine triphosphate (dCTP),"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0045191:Deoxy cytidine triphosphate [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0011485:Deoxycytidine [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0146894:triphosphate [Inorganic Chemical]

Phrase: "deoxyguanosine triphosphate (dGTP),"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0057430:Deoxy guanosine triphosphate [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0011503:Deoxyguanosine [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0146894:triphosphate [Inorganic Chemical]

Phrase: "400 M deoxyuridine triphosphate (dUTP),"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0057470:deoxyuridine triphosphate [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0011535:Deoxyuridine [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0146894:triphosphate [Inorganic Chemical]

Phrase: "1.25 U AmpliTaq gold DNA polymerase,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   818   C0012892:DNA Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   795   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   795   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "0.5 U AmpErase uracil N-glycosylase (UNG),"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   845   C0077845:Uracil N-Glycosylase [Amino Acid, Peptide, or Protein,Enzyme]
   795   C1817832:glycosylase [Molecular Function]

Phrase: "and"

Phrase: "concentration of ASO primer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0086045:Concentration [Mental Process]
   753   C1446561:Concentration [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.49: JH primer (5'-ACCTGAGGAGACGGTGACCAG-3') and ASO TaqMan probe were optimized for each ASO assay. 

Phrase: "JH primer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(5'-ACCTGAGGAGACGGTGACCAG-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "ASO TaqMan probe"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0182400:Probe [Medical Device]
   804   C1704681:Probe [Gene or Genome]
   804   C2347609:Probe [Chemical Viewed Functionally]
   804   C3536729:Probe [Manufactured Object]

Phrase: "were"

Phrase: "optimized for each ASO assay."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0002085:Allele [Gene or Genome]
   748   C0005507:Assay [Laboratory Procedure]
   748   C0028953:Oligonucleotide [Nucleic Acid, Nucleoside, or Nucleotide]
   748   C0205369:Specific [Qualitative Concept]
   748   C0243073:assay [Qualitative Concept]
   748   C1510438:Assay [Laboratory Procedure]
   748   C1552740:specific [Intellectual Product]
Processing 00000000.tx.50: For the -actin assay, forward and reverse primer concentrations were 0.3 M (each) and the -actin probe concentration was 0.2 M. 

Phrase: "For the -actin assay,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0005507:Assay [Laboratory Procedure]
   861   C0243073:assay [Qualitative Concept]
   861   C1510438:Assay [Laboratory Procedure]

Phrase: "forward"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439780:Forward [Spatial Concept]

Phrase: "and"

Phrase: "reverse primer concentrations"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0086045:Concentrations [Mental Process]
   793 E C1446561:Concentration [Quantitative Concept]
   743 E C1880165:Concentrated [Biomedical or Dental Material]
   734   C1953384:Reverse primer [Amino Acid, Peptide, or Protein]

Phrase: "were"

Phrase: "0.3"

Phrase: "M ("

Phrase: "each"

Phrase: ")"

Phrase: "and"

Phrase: "the -actin probe concentration"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0086045:Concentration [Mental Process]
   827   C1446561:Concentration [Quantitative Concept]
   755 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "was"

Phrase: "0.2 M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.51: Reaction volumes were adjusted to 50 L with dH2O. 

Phrase: "Reaction volumes"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0449468:volumes [Quantitative Concept]
   827 E C1690016:% volume [Qualitative Concept]
   827 E C1705102:Volume [Intellectual Product]
   827 E C2700258:Volume [Laboratory Procedure]

Phrase: "were"

Phrase: "adjusted to 50 L"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0456081:Adjusted [Functional Concept]

Phrase: "with dH2O."
Processing 00000000.tx.52: For generation of a standard curve, the TaqMan DNA template reagents kit containing DNA of known concentrations was used. 

Phrase: "For generation"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0079411:Generation [Temporal Concept]
  1000   C3146294:Generation [Activity]
   907 E C1414672:Genesis [Gene or Genome]
   907 E C2984892:Genesis [Gene or Genome]

Phrase: "of a standard curve,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205134:Curve [Spatial Concept]

Phrase: "the TaqMan DNA template reagents kit containing DNA of known concentrations"

Phrase: "was"

Phrase: "used."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.53: All PCR consumables except the oligonucleotides previously mentioned were supplied by PE Applied Biosystems (Foster City, CA). 

Phrase: "All PCR consumables except the oligonucleotides previously"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   708   C1550507:consumable [Idea or Concept]

Phrase: "mentioned"

Phrase: "were"

Phrase: "supplied by PE Applied Biosystems"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
   760   C0185125:Applied [Health Care Activity]
   760   C1999230:Supplied [Activity]
   726 E C0243163:supply [Idea or Concept]
   726 E C0699914:supply [Quantitative Concept]
   726 E C1314650:SUPPLY, NOT OTHERWISE SPECIFIED [Medical Device]
   726 E C1561604:supply [Functional Concept]
   726 E C1875802:SUPPLY [Medical Device]

Phrase: "(Foster City,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0008848:City [Geographic Area]
   861   C0242298:foster [Daily or Recreational Activity]
   861   C0344349:foster [Family Group]
   861   C3262831:City [Clinical Attribute]

Phrase: "CA)."
Processing 00000000.tx.54: The thermal cycling conditions included 2 minutes at 50C and 10 minutes at 95C followed by 45 cycles of 95C for 0.15 minutes and 58C for 1 minute. 

Phrase: "The thermal cycling conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   793   C0012634:condition [Disease or Syndrome]
   793   C0348080:Condition [Qualitative Concept]
   793   C1705253:Condition [Conceptual Entity]
   743 E C0009647:Conditioned [Mental Process]
   743 E C1701901:Conditional [Qualitative Concept]
   743 E C1963686:Conditional [Functional Concept]
   721 E C1519605:Conditionality [Conceptual Entity]

Phrase: "included"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0332257:included [Functional Concept]
  1000   C3538986:INCLUDED [Gene or Genome]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "2 minutes at 50C"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0439232:minute [Temporal Concept]
   770   C0700321:minute [Quantitative Concept]
   770   C0702093:/minute [Temporal Concept]
   770   C1282918:Minute [Quantitative Concept]
   770   C2347166:Minute [Quantitative Concept]

Phrase: "and"

Phrase: "10 minutes at 95C"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0456692:/10 minutes [Temporal Concept]
   833   C1442446:10 Minutes [Temporal Concept]
   770   C0439232:minute [Temporal Concept]
   770   C0700321:minute [Quantitative Concept]
   770   C0702093:/minute [Temporal Concept]
   770   C1282918:Minute [Quantitative Concept]
   770   C2347166:Minute [Quantitative Concept]

Phrase: "followed by 45 cycles of 95C"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0332283:Followed by [Temporal Concept]
           followed
   719   C1511572:Cycle [Temporal Concept]
   719 E C1719822:Follow [Intellectual Product]

Phrase: "for 0.15 minutes"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C1442447:15 Minutes [Temporal Concept]
   827   C0439232:minute [Temporal Concept]
   827   C0700321:minute [Quantitative Concept]
   827   C0702093:/minute [Temporal Concept]
   827   C1282918:Minute [Quantitative Concept]
   827   C2347166:Minute [Quantitative Concept]

Phrase: "and"

Phrase: "58C for 1 minute."
Processing 00000000.tx.55: All reactions were performed in the ABI PRISM 7700 Sequence Detector (PE Applied Biosystems). 

Phrase: "All reactions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0443286:Reaction [Functional Concept]
   966   C1114821:Reaction [Clinical Attribute]

Phrase: "were"

Phrase: "performed in the ABI PRISM 7700 Sequence Detector"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   744   C0004793:Sequence [Nucleotide Sequence]
   744   C0162326:Sequence [Nucleotide Sequence]
   744   C0162327:Sequence [Nucleotide Sequence]
   744   C0180392:Detector [Medical Device]
   744   C0814195:PRISM [Intellectual Product]
   744   C0884358:Performed [Functional Concept]
   744   C1328319:ABI [Clinical Attribute]
   744   C1519249:Sequence [Functional Concept]
   744   C1705235:Detector [Manufactured Object]
   711 E C2947996:Perform [Pharmacologic Substance]

Phrase: "(PE Applied Biosystems"

Phrase: ")."
Processing 00000000.tx.56: Collection and analysis of data were done with Sequence Detector Software version 1.6 (PE Applied Biosystems). 

Phrase: "Collection"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1516698:Collection [Functional Concept]
  1000   C1704814:Collection [Idea or Concept]
   928 E C1516695:Collected [Idea or Concept]

Phrase: "and"

Phrase: "analysis of data"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   858   C0010992:Data Analysis [Occupational Activity]
   790   C0002778:Analysis [Laboratory Procedure]
   790   C0936012:Analysis [Research Activity]
   790   C1524024:analysis [Functional Concept]

Phrase: "were"

Phrase: "done with Sequence Detector Software version 1.6"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   744   C0004793:Sequence [Nucleotide Sequence]
   744   C0037585:Software [Intellectual Product,Manufactured Object]
   744   C0162326:Sequence [Nucleotide Sequence]
   744   C0162327:Sequence [Nucleotide Sequence]
   744   C0180392:Detector [Medical Device]
   744   C0333052:Version [Functional Concept]
   744   C1272695:Done [Qualitative Concept]
   744   C1519249:Sequence [Functional Concept]
   744   C1705235:Detector [Manufactured Object]
   744   C2607870:Version [Spatial Concept]
   744   C2746065:Done [Temporal Concept]

Phrase: "(PE Applied Biosystems"

Phrase: ")."
Processing 00000000.tx.57: Blood samples were obtained at weeks 0, 8, 14, and 30 for the assessment of the levels of clonal B cells. 

Phrase: "Blood samples"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0178913:blood samples [Body Substance]
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "obtained at weeks 0,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0439230:weeks [Temporal Concept]
   770   C1301820:Obtained [Functional Concept]
   737 E C0332174:/week [Temporal Concept]
   737 E C1706701:Obtain [Activity]

Phrase: "8,"

Phrase: "14,"

Phrase: "and"

Phrase: "30 for the assessment of the levels of clonal B cells."
Meta Candidates (Total=15; Excluded=6; Pruned=0; Remaining=9)
   756   C0004561:B-Cells [Cell]
   738   C0007634:Cells [Cell]
   738   C0441889:Levels [Qualitative Concept]
   738   C1261322:Assessment [Health Care Activity]
   738   C1516048:Assessment [Activity]
   738   C1522642:Clonal [Tissue]
   738   C1704387:Clonal [Qualitative Concept]
   738   C3282337:Cells [Cell]
   718   C0009013:Clone Cells [Cell]
   704 E C0456079:Level [Classification]
   704 E C1269647:Cell [Cell]
   704 E C1547707:Level [Geographic Area]
   704 E C1704653:Cell [Medical Device]
   704 E C1948049:Cell [Spatial Concept]
   704 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.58: For each sample, 6 aliquots with approximately 1 g DNA were subjected to analysis, 3 samples for quantitation of -actin and 3 samples for clonal cells. 

Phrase: "For each sample,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]

Phrase: "6 aliquots with approximately 1 g DNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   714   C1510844:Aliquot [Quantitative Concept]

Phrase: "were"

Phrase: "subjected to analysis,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0002778:Analysis [Laboratory Procedure]
   790   C0936012:Analysis [Research Activity]
   790   C1524024:analysis [Functional Concept]
   756   C0681850:Subject [Group]
   756   C1550501:{Subject} [Idea or Concept]
   756   C1706203:Subject [Idea or Concept]
   756   C2349001:Subject [Human]
   756   C2697811:Subject [Functional Concept]

Phrase: "3 samples for quantitation of -actin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C0370003:Sample [Substance]
   719   C2347026:Sample [Conceptual Entity]

Phrase: "and"

Phrase: "3 samples for clonal cells."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C0370003:Sample [Substance]
   726   C2347026:Sample [Conceptual Entity]
Processing 00000000.tx.59: Nested ASO RT-PCR including approximately 0.5 g total RNA was performed as described previously.13  Results and discussion Top Abstract Introduction Study design Results and discussion References  For the development of an Id vaccination strategy in MM patients we are focusing on stage I based on the observation that patients with early-stage MM may naturally exhibit mainly type I Idspecific T cells, whereas in late-stage, type II Id-specific T cells seemed to prevail.1 In the present study, half of the patients had an Id-specific proliferative T-cell response before vaccination, which is in agreement with our earlier observations.15 In stage I, the general T-cell functions also seem to be well preserved (F. Mozzafari, unpublished data, January 2003). 

Phrase: "Nested ASO RT-PCR"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   906   C0242574:Nested Polymerase Chain Reaction [Molecular Biology Research Technique]
   835   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   822   C0133828:oligonucleotide polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   793   C0337112:Chain [Manufactured Object]
   793   C0443286:Reaction [Functional Concept]
   793   C1114821:Reaction [Clinical Attribute]
   793   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   793   C1524075:Chain [Idea or Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "approximately 0.5 g total RNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously.13  Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C1274040:Result [Functional Concept]
   793   C1546471:Result [Idea or Concept]
   793   C2825142:Result [Finding]

Phrase: "and"

Phrase: "discussion Top Abstract Introduction Study design Results"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   829   C0683954:study results [Finding]
   762   C1274040:Result [Functional Concept]
   762   C1546471:Result [Idea or Concept]
   762   C2825142:Result [Finding]

Phrase: "and"

Phrase: "discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557061:Discussion [Therapeutic or Preventive Procedure]
  1000   C2584313:Discussion [Social Behavior]

Phrase: "References  For the development of an Id vaccination strategy"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   742   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
   742   C0042196:Vaccination [Therapeutic or Preventive Procedure]
   742   C0243107:development [Physiologic Function]
   742   C0678723:Development [Organism Function]
   742   C0679199:strategy [Mental Process]
   742   C1514811:Reference [Idea or Concept]
   742   C1527148:Development [Functional Concept]
   742   C1706462:Reference [Conceptual Entity]

Phrase: "in MM patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0026764:Multiple Myeloma [Neoplastic Process]

Phrase: "we"

Phrase: "are"

Phrase: "focusing"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0000936:focusing [Clinical Attribute]
  1000   C2981153:Focusing [Finding]
   966 E C0205234:Focus [Spatial Concept]
   966 E C1285542:focus [Functional Concept]

Phrase: "on stage I"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0441766:Stage I [Intellectual Product]
   827   C0021966:I- [Inorganic Chemical]
   827   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "based on the observation"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C0302523:Observation [Research Activity]
   770   C0700325:observation [Health Care Activity]
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   770   C1964257:Observation [Diagnostic Procedure]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "that patients with early-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:Patients [Patient or Disabled Group]

Phrase: "stage"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205390:Stage [Temporal Concept]
  1000   C1300072:Stage [Clinical Attribute]
  1000   C1306673:Stage [Qualitative Concept]

Phrase: "MM"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "may"

Phrase: "naturally"

Phrase: "exhibit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015272:Exhibit [Intellectual Product]

Phrase: "mainly type I Idspecific T cells,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   874   C1519720:Type I Cell [Cell]
   859   C0449475:type cell [Intellectual Product]
   827   C0039194:T-Cells [Cell]
   799   C0007634:Cells [Cell]
   799   C3282337:Cells [Cell]
   766 E C1269647:Cell [Cell]
   766 E C1704653:Cell [Medical Device]
   766 E C1948049:Cell [Spatial Concept]

Phrase: "whereas in late-stage,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C1279941:Late stage [Temporal Concept]
   770   C0205087:Late [Temporal Concept]
   770   C0205390:Stage [Temporal Concept]
   770   C1300072:Stage [Clinical Attribute]
   770   C1306673:Stage [Qualitative Concept]

Phrase: "type II Id-specific T cells"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   893   C1519715:Type II Cell [Cell]
   878   C0449475:type cell [Intellectual Product]
   827   C0039194:T-Cells [Cell]
   799   C0007634:Cells [Cell]
   799   C3282337:Cells [Cell]
   766 E C1269647:Cell [Cell]
   766 E C1704653:Cell [Medical Device]
   766 E C1948049:Cell [Spatial Concept]

Phrase: "seemed to"

Phrase: "prevail.1 In the present study,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0150312:Present [Quantitative Concept]
   753   C0449450:Present [Idea or Concept]
   753   C0557651:Study [Manufactured Object]
   753   C2603343:Study [Research Activity]
   753   C3152857:Prevail [Pharmacologic Substance]

Phrase: "half of the patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2825407:Half [Quantitative Concept]

Phrase: "had"

Phrase: "an Id-specific proliferative T-cell response before vaccination,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0871261:Response [Organism Attribute]
   742   C1704632:Response [Finding]
   742   C1706817:Response [Intellectual Product]
   742   C2911692:Response [Mental Process]

Phrase: "which"

Phrase: "is in agreement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0680240:Agreement [Social Behavior]

Phrase: "with our earlier observations.15"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   827   C0302523:observations [Research Activity]
   827   C0700325:observations [Health Care Activity]
   827   C3244290:observations [Functional Concept]
   793   C1279919:Early [Temporal Concept]
   793 E C1964257:Observation [Diagnostic Procedure]
   743 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "In stage I,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441766:Stage I [Intellectual Product]
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "the general T-cell functions also"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   840   C0007613:cell functions [Cell Function]
   840   C0039194:T-cell [Cell]
   804   C0007634:Cell [Cell]
   804   C0542341:Functions [Functional Concept]
   804   C1269647:Cell [Cell]
   804   C1704653:Cell [Medical Device]
   804   C1948049:Cell [Spatial Concept]
   771 E C0031843:function [Physiologic Function]
   771 E C0700205:FUNCTION [Classification]
   771 E C1705273:Function [Intellectual Product]
   721 E C0205245:Functional [Functional Concept]
   721 E C2700217:Functional [Conceptual Entity]

Phrase: "seem"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "well preserved"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0033085:Preserved [Laboratory Procedure]
   861   C0205170:Well [Qualitative Concept]
   861   C3146287:Well [Manufactured Object]

Phrase: "(F. Mozzafari,"

Phrase: "unpublished data,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "January 2003"

Phrase: ")."
Processing 00000000.tx.60: In 8 of 10 of the stage I patients considered for the study, we were able to identify the myeloma-specific immunoglobulin heavy chain gene (IgH) DNA sequence. 

Phrase: "In 8"

Phrase: "of 10"

Phrase: "of the stage I patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0441766:Stage I [Intellectual Product]

Phrase: "considered for the study,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0557651:Study [Manufactured Object]
   770   C0750591:considered [Idea or Concept]
   770   C2603343:Study [Research Activity]

Phrase: "we"

Phrase: "were"

Phrase: "able to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0085732:Able [Organism Attribute]
   861   C1299581:Able [Finding]

Phrase: "identify"

Phrase: "the myeloma-specific immunoglobulin heavy chain gene (IgH) DNA sequence."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   812   C0162326:DNA Sequence [Nucleotide Sequence]
           Sequence
   793   C0004793:Sequence [Nucleotide Sequence]
   793   C0162327:Sequence [Nucleotide Sequence]
   793   C1519249:Sequence [Functional Concept]
   721 E C1548958:Sequential [Idea or Concept]
   721 E C1705294:Sequential [Qualitative Concept]
Processing 00000000.tx.61: For these 8 patients we designed a patient-specific ASO primer and a patient-specific dual-labeled fluorogenic probe (ASO TaqMan probe) corresponding to CDR3 (Table 1). 

Phrase: "For these 8 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "we"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "a patient-specific ASO primer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0206415:Oligonucleotide Primer [Nucleic Acid, Nucleoside, or Nucleotide]
           Primer

Phrase: "and"

Phrase: "a patient-specific dual-labeled fluorogenic probe"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   799   C0182400:Probe [Medical Device]
   799   C1704681:Probe [Gene or Genome]
   799   C2347609:Probe [Chemical Viewed Functionally]
   799   C3536729:Probe [Manufactured Object]

Phrase: "(ASO TaqMan probe"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0182400:Probe [Medical Device]
   804   C1704681:Probe [Gene or Genome]
   804   C2347609:Probe [Chemical Viewed Functionally]
   804   C3536729:Probe [Manufactured Object]

Phrase: ")"

Phrase: "corresponding to CDR3"
Meta Candidates (Total=14; Excluded=6; Pruned=0; Remaining=8)
   833   C0887928:Complementarity Determining Region 3 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   800   C0021024:Complementarity-Determining Region [Amino Acid, Peptide, or Protein,Immunologic Factor]
   750   C1268228:Cell region [Cell Component]
   744   C0007634:Cells [Cell]
   744   C0017446:Region [Geographic Area]
   744   C0205147:Region [Spatial Concept]
   744   C1524063:Using [Functional Concept]
   744   C3282337:Cells [Cell]
   711 E C0042153:use [Functional Concept]
   711 E C0457083:Use [Functional Concept]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1947944:Use [Intellectual Product]
   711 E C1948049:Cell [Spatial Concept]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.62: The CDR3 primers were tested on a panel of DNA from different patients, ensuring that the primers amplified only an IgH sequence from the patient of interest. 

Phrase: "The CDR3 primers"
Meta Candidates (Total=18; Excluded=8; Pruned=0; Remaining=10)
   861   C0887928:Complementarity Determining Region 3 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   835   C0021024:Complementarity-Determining Region [Amino Acid, Peptide, or Protein,Immunologic Factor]
   834   C1268228:Cell region [Cell Component]
   795   C0007634:THE CELL [Cell]
           Cells
   793   C0017446:Region [Geographic Area]
   793   C0205147:Region [Spatial Concept]
   793   C1524063:Using [Functional Concept]
   793   C3282337:Cells [Cell]
   760 E C0042153:use [Functional Concept]
   760   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]
   760 E C0457083:Use [Functional Concept]
   760 E C1269647:Cell [Cell]
   760 E C1704653:Cell [Medical Device]
   760 E C1947944:Use [Intellectual Product]
   760 E C1948049:Cell [Spatial Concept]
   721 E C0205276:Regional [Spatial Concept]
   721 E C1947913:Regional [Spatial Concept]

Phrase: "were"

Phrase: "tested on a panel of DNA"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   753   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0392366:tested [Intellectual Product]
   753   C0441833:Panel [Idea or Concept]
   753   C1999270:Panel [Intellectual Product]
   753   C3537156:Panel [Manufactured Object]
   719 E C0022885:Test [Laboratory Procedure]
   719 E C0039593:Test [Functional Concept]

Phrase: "from different patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "ensuring"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0218063:Ensure [Food]

Phrase: "that"

Phrase: "the primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "amplified"

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "an IgH sequence from the patient of interest."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   738   C0004793:Sequence [Nucleotide Sequence]
   738   C0162326:Sequence [Nucleotide Sequence]
   738   C0162327:Sequence [Nucleotide Sequence]
   738   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.63: The forward CDR3 primer was designed to span the V-D junction, and the CDR3 TaqMan probe was designed to span the D-J junction giving maximum specificity (Table 1). 

Phrase: "The forward CDR3 primer"
Meta Candidates (Total=20; Excluded=8; Pruned=0; Remaining=12)
   879   C1953382:Forward primer [Cell]
   849   C0887928:Complementarity Determining Region 3 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0021024:Complementarity-Determining Region [Amino Acid, Peptide, or Protein,Immunologic Factor]
   825   C1268228:Cell region [Cell Component]
   800   C0007634:THE CELL [Cell]
           Cells
   791   C0017446:Region [Geographic Area]
   791   C0205147:Region [Spatial Concept]
   791   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]
   791   C0439780:Forward [Spatial Concept]
   791   C1524063:Using [Functional Concept]
   791   C3282337:Cells [Cell]
   758 E C0042153:use [Functional Concept]
   758 E C0457083:Use [Functional Concept]
   758 E C1269647:Cell [Cell]
   758 E C1704653:Cell [Medical Device]
   758 E C1947944:Use [Intellectual Product]
   758 E C1948049:Cell [Spatial Concept]
   720 E C0205276:Regional [Spatial Concept]
   720 E C1947913:Regional [Spatial Concept]

Phrase: "was"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "span"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1711300:Span [Conceptual Entity]
  1000   C2700613:Span [Quantitative Concept]

Phrase: "the V-D junction,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205144:Junction [Spatial Concept]
   827   C1706311:Junction [Medical Device]
   734   C0231965:V D [Laboratory or Test Result]

Phrase: "and"

Phrase: "the CDR3 TaqMan probe"
Meta Candidates (Total=21; Excluded=8; Pruned=0; Remaining=13)
   849   C0887928:Complementarity Determining Region 3 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0021024:Complementarity-Determining Region [Amino Acid, Peptide, or Protein,Immunologic Factor]
   825   C1268228:Cell region [Cell Component]
   791   C0007634:Cells [Cell]
           THE CELL
   791   C0017446:Region [Geographic Area]
   791   C0182400:Probe [Medical Device]
   791   C0205147:Region [Spatial Concept]
   791   C1524063:Using [Functional Concept]
   791   C1704681:Probe [Gene or Genome]
   791   C2347609:Probe [Chemical Viewed Functionally]
   791   C3282337:Cells [Cell]
   791   C3536729:Probe [Manufactured Object]
   758 E C0042153:use [Functional Concept]
   758 E C0457083:Use [Functional Concept]
   758 E C1269647:Cell [Cell]
   758 E C1704653:Cell [Medical Device]
   758 E C1947944:Use [Intellectual Product]
   758 E C1948049:Cell [Spatial Concept]
   720 E C0205276:Regional [Spatial Concept]
   720 E C1947913:Regional [Spatial Concept]

Phrase: "was"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "span"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1711300:Span [Conceptual Entity]
  1000   C2700613:Span [Quantitative Concept]

Phrase: "the D-J junction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205144:Junction [Spatial Concept]
   827   C1706311:Junction [Medical Device]

Phrase: "giving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1947971:Give [Functional Concept]

Phrase: "maximum specificity"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0037791:Specificity [Quantitative Concept]
   861   C1511884:Specificity [Quantitative Concept]
   789 E C0205369:Specific [Qualitative Concept]
   789 E C1552740:specific [Intellectual Product]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.64: View this table: [in this window] [in a new window]  Table 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 1."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.65: Nucleotide-specific IgH sequences of 8 patients with MM  Sequential analyses of circulating blood myeloma B cells were performed (Figure 1). 

Phrase: "Nucleotide-specific IgH"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   901   C0017351:Immunoglobulin heavy chain gene [Gene or Genome]
           Immunoglobulin Heavy Gene
   861   C0021034:Immunoglobulin Heavy Chain [Amino Acid, Peptide, or Protein,Immunologic Factor]
   858   C0017350:Immunoglobulin gene [Gene or Genome]
   839   C1302674:Immunoglobulin chain [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C1420192:heavy chain [Gene or Genome]
   799   C0017337:Gene [Gene or Genome]
   799   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   799   C0337112:Chain [Manufactured Object]
   799   C0439539:Heavy [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1621846:immunoglobulin [Molecular Function]

Phrase: "sequences of 8 patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0004793:Sequence [Nucleotide Sequence]
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0162326:Sequence [Nucleotide Sequence]
   770   C0162327:Sequence [Nucleotide Sequence]
   770   C1519249:Sequence [Functional Concept]

Phrase: "with MM  Sequential analyses"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   779   C0002778:Analysis [Laboratory Procedure]
   779   C0936012:Analysis [Research Activity]
   779   C1524024:analysis [Functional Concept]

Phrase: "of circulating blood myeloma B cells"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   875   C0005773:Blood Cells [Cell]
   840   C0004561:B-Cells [Cell]
   836   C0333843:Myeloma cell [Cell]
   831 E C2328697:Hemal cell [Cell]
   804   C0007634:Cells [Cell]
   804   C3282337:Cells [Cell]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "(Figure 1"

Phrase: ")."
Processing 00000000.tx.66: In 2 of 8 patients, circulating clonal tumor cells were detectable by nested ASO RT-PCR, but below reliable quantitation by real-time ASO PCR. 

Phrase: "In 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "of 8 patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "circulating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0175630:Circulating [Functional Concept]

Phrase: "clonal tumor cells"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   901   C0431085:Tumor cells [Cell]
   877   C0009013:Clone Cells [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "detectable by nested ASO RT-PCR,"

Phrase: "but below reliable quantitation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0233535:but [Mental or Behavioral Dysfunction]
   770   C1709793:Quantitation [Quantitative Concept]

Phrase: "by real-time ASO PCR."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   911   C1709846:Real-Time Polymerase Chain Reaction [Molecular Biology Research Technique]
   878   C0034746:time reaction [Temporal Concept]
   835   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0133828:oligonucleotide polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   793   C0337112:Chain [Manufactured Object]
   793   C0443286:Reaction [Functional Concept]
   793   C1114821:Reaction [Clinical Attribute]
   793   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   793   C1524075:Chain [Idea or Concept]
Processing 00000000.tx.67: The sensitivity of the real-time ASO PCR is in the range of 1 clonal tumor B cell in 105 lymphocytes or 5 clonal tumor B cells in 105 lymphocytes and 1 clonal tumor B cell in 106 lymphocytes for nested ASO RTPCR.12,13 Of the remaining 6 patients, 3 patients were immunized with the Id immunoglobulin together with IL-12 alone (MM-1, MM-3, and MM-6) and 3 patients received a combination of the adjuvant cytokines IL-12 and GM-CSF (MM-2, MM-4, and MM-5). 

Phrase: "The sensitivity of the real-time ASO PCR"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   736   C0036667:Sensitivity [Quantitative Concept]
   736   C0312418:Sensitivity [Mental Process]
   736   C0427965:Sensitivity [Finding]
   736   C1511883:Sensitivity [Quantitative Concept]
   736   C1522640:Sensitivity [Qualitative Concept]
   736   C2346484:SENSITIVITY [Phenomenon or Process]
   736   C2349185:Sensitivity [Qualitative Concept]

Phrase: "is in the range of 1 clonal tumor B cell"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   760   C0004561:B-cell [Cell]
   757   C0431085:Tumor cell [Cell]
   757   C0597032:Tumor Cell [Cell]
   739   C0007634:Cell [Cell]
   739   C0027651:Tumor [Neoplastic Process]
   739   C1269647:Cell [Cell]
   739   C1514721:Range [Quantitative Concept]
   739   C1522642:Clonal [Tissue]
   739   C1578706:Tumor [Intellectual Product]
   739   C1704387:Clonal [Qualitative Concept]
   739   C1704653:Cell [Medical Device]
   739   C1948049:Cell [Spatial Concept]
   739   C2348147:Range [Quantitative Concept]
   739   C3273930:Tumor [Finding]
   739   C3542016:Range [Intellectual Product]
   722   C0009013:Cell Clone [Cell]

Phrase: "in 105 lymphocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0024264:Lymphocytes [Cell]

Phrase: "or"

Phrase: "5 clonal tumor B cells in 105 lymphocytes"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   770   C0004561:B-Cells [Cell]
           Lymphocytes B
   767   C0431085:Tumor cells [Cell]
   750 E C0597032:Tumor Cell [Cell]
   744   C0007634:Cells [Cell]
   744   C3282337:Cells [Cell]
   731   C0009013:Clone Cells [Cell]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "1 clonal tumor B cell in 106 lymphocytes"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   770   C0004561:B-cell [Cell]
           Lymphocytes B
   767   C0431085:Tumor cell [Cell]
   767   C0597032:Tumor Cell [Cell]
   744   C0007634:Cell [Cell]
   744   C1269647:Cell [Cell]
   744   C1704653:Cell [Medical Device]
   744   C1948049:Cell [Spatial Concept]
   731   C0009013:Cell Clone [Cell]

Phrase: "for nested ASO RTPCR.12,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0002085:Allele [Gene or Genome]
   799   C0028953:Oligonucleotide [Nucleic Acid, Nucleoside, or Nucleotide]
   799   C0205369:Specific [Qualitative Concept]
   799   C0599161:RT-PCR [Molecular Biology Research Technique]
   799   C1552740:specific [Intellectual Product]

Phrase: "13 Of the remaining 6 patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0030705:Patients [Patient or Disabled Group]
   753   C1527428:Remaining [Qualitative Concept]

Phrase: "3 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "immunized with the Id immunoglobulin"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   797   C0021013:Immunoglobulin idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Idiotype
   760   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C1621846:immunoglobulin [Molecular Function]

Phrase: "together with IL-12"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "(MM-1,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "MM-3,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "and"

Phrase: "MM-6"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: ")"

Phrase: "and"

Phrase: "3 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a combination of the adjuvant cytokines IL-12"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0205195:Combination [Qualitative Concept]
   744   C1947911:Combination [Physical Object]

Phrase: "and"

Phrase: "GM-CSF"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
  1000   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
  1000   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   937   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   937   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   933   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0018183:granulocyte [Cell]
   804   C0024432:macrophage [Cell]
   804   C0439158:colony [Quantitative Concept]
   804   C1521761:Factor [Functional Concept]
   804   C1947989:Colony [Cell]
   804   C1948023:Stimulating [Natural Phenomenon or Process]
   804   C2827422:Factor [Conceptual Entity]

Phrase: "(MM-2,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "MM-4,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "and"

Phrase: "MM-5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.68: No other treatment was given during the study period. 

Phrase: "No"

Phrase: "other treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "was"

Phrase: "given during the study period."
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   760   C0439531:/period [Temporal Concept]
   760   C0557651:Study [Manufactured Object]
   760   C1442162:GIVEN [Conceptual Entity]
   760   C1550718:given [Idea or Concept]
   760   C1948053:Period [Temporal Concept]
   760   C2603343:Study [Research Activity]
   760   C3244317:given [Intellectual Product]
   726 E C1947971:Give [Functional Concept]
Processing 00000000.tx.69: View larger version (17K): [in this window] [in a new window]  Figure 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(17K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 1."
Processing 00000000.tx.70: Real-time ASO PCR results. 

Phrase: "Real-time ASO PCR results."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   758   C1274040:Result [Functional Concept]
   758   C1546471:Result [Idea or Concept]
   758   C2825142:Result [Finding]
   727   C1709846:Real-Time Polymerase Chain Reaction [Molecular Biology Research Technique]
   700   C0034746:time reaction [Temporal Concept]
Processing 00000000.tx.71: Blood clonal myeloma tumor B-cell levels measured by real-time ASO PCR (see "Study design") in 6 MM patients immunized with the autologous Id during 30 weeks of follow-up. 

Phrase: "Blood clonal myeloma tumor B-cell levels"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   795   C0441889:Levels [Qualitative Concept]
   762 E C0456079:Level [Classification]
   762 E C1547707:Level [Geographic Area]
   762 E C2946261:Level [Pharmacologic Substance]
   710   C0005773:Blood cell [Cell]

Phrase: "measured by real-time ASO PCR"
Meta Candidates (Total=22; Excluded=2; Pruned=0; Remaining=20)
   820   C1709846:Real-Time Polymerase Chain Reaction [Molecular Biology Research Technique]
   782   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   760   C0133828:oligonucleotide polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C1550177:Real Time [Idea or Concept]
   757   C0034746:Reaction Time [Temporal Concept]
   739   C0002085:Allele [Gene or Genome]
   739   C0028953:Oligonucleotide [Nucleic Acid, Nucleoside, or Nucleotide]
   739   C0040223:Time [Temporal Concept]
   739   C0205369:Specific [Qualitative Concept]
   739   C0237400:Real [Qualitative Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0443286:Reaction [Functional Concept]
   739   C0444706:Measured [Qualitative Concept]
   739   C1114821:Reaction [Clinical Attribute]
   739   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C1524075:Chain [Idea or Concept]
   739   C1552740:specific [Intellectual Product]
   739   C3272377:REAL [Intellectual Product]
   739   C3541383:Time [Temporal Concept]
   739   C3541902:MEASURED [Diagnostic Procedure]
   706 E C0079809:Measure [Quantitative Concept]
   706 E C0242485:Measure [Functional Concept]

Phrase: "(see ""Study design"""
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   901   C0035171:Study Design [Research Activity]
   901   C2983265:Study Design [Intellectual Product]
           DESIGN
   901   C2986888:Study Design [Research Activity]
   827   C0557651:Study [Manufactured Object]
   827   C1707689:Design [Activity]
   827   C2603343:Study [Research Activity]

Phrase: ")"

Phrase: "in 6 MM patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:Patients [Patient or Disabled Group]

Phrase: "immunized with the autologous Id"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0439859:Autologous [Qualitative Concept]

Phrase: "during 30 weeks"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]

Phrase: "of follow-up."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0589120:Follow-up [Finding]
  1000   C1522577:follow-up [Health Care Activity]
  1000   C1704685:FOLLOW-UP [Intellectual Product]
  1000   C3274571:FOLLOW-UP [Health Care Activity]
   861   C0332283:follow [Temporal Concept]
   861   C1719822:Follow [Intellectual Product]
Processing 00000000.tx.72: Arrows indicate immunization times. 

Phrase: "Arrows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0336721:arrows [Manufactured Object]

Phrase: "indicate"

Phrase: "immunization times."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0040223:times [Temporal Concept]
   861   C1632851:Times [Quantitative Concept]
   827 E C3541383:Time [Temporal Concept]
   789 E C0442043:Temporal [Spatial Concept]
   789 E C2362314:Temporal [Temporal Concept]
Processing 00000000.tx.73: Three patients received IL-12 alone (MM-1, MM-3, and MM-6) and 3 patients received IL-12 plus GM-CSF (MM-2, MM-4, and MM-5) as adjuvants. 

Phrase: "Three patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "IL-12"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "(MM-1,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "MM-3,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "and"

Phrase: "MM-6"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: ")"

Phrase: "and"

Phrase: "3 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "IL-12 plus GM-CSF"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   890   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
   890   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   890   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
   890   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   864   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   835   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   793   C0018183:granulocyte [Cell]
   793   C0024432:macrophage [Cell]
   793   C0439158:colony [Quantitative Concept]
   793   C1521761:Factor [Functional Concept]
   793   C1947989:Colony [Cell]
   793   C1948023:Stimulating [Natural Phenomenon or Process]
   793   C2827422:Factor [Conceptual Entity]

Phrase: "(MM-2,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "MM-4,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "and"

Phrase: "MM-5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: ")"

Phrase: "as adjuvants."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0001551:Adjuvant, NOS [Immunologic Factor,Pharmacologic Substance]
   966   C0001552:Adjuvant [Chemical Viewed Functionally]
   966   C1522673:Adjuvant [Functional Concept]
Processing 00000000.tx.74: The number of IgH copies detected at initiation of vaccination was set to 100%. 

Phrase: "The number of IgH copies"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   782   C0178655:Gene Copy Number [Quantitative Concept]
   750   C1707513:Copy Number [Quantitative Concept]
   744   C0237753:*Number [Quantitative Concept]
   744   C0449788:Number [Quantitative Concept]

Phrase: "detected at initiation of vaccination"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0042196:Vaccination [Therapeutic or Preventive Procedure]
   760   C0442726:Detected [Finding]
   760   C0589507:Initiation [Mental Process]
   760   C1158830:Initiation [Genetic Function]
   760   C1511790:Detected [Therapeutic or Preventive Procedure]
   760   C1704686:Initiation [Functional Concept]

Phrase: "was"

Phrase: "set to 100%."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0036849:Set [Mental Process]
   790   C1442518:Set [Functional Concept]
   790   C1705195:Set [Conceptual Entity]
Processing 00000000.tx.75: The values during follow-up are given as percent of the initial sample. 

Phrase: "The values during follow-up"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0042295:Values [Qualitative Concept]
   726 E C1522609:Value [Quantitative Concept]

Phrase: "are"

Phrase: "given as percent of the initial sample."
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   778   C2735567:Initial sample [Substance]
   748   C0205265:Initial [Temporal Concept]
   748   C0370003:Sample [Substance]
   748   C0439165:Percent [Quantitative Concept]
   748   C1279901:Initial [Qualitative Concept]
   748   C1442162:GIVEN [Conceptual Entity]
   748   C1550718:given [Idea or Concept]
   748   C1555582:Initial [Idea or Concept]
   748   C1705685:INITIAL [Functional Concept]
   748   C2347026:Sample [Conceptual Entity]
   748   C3244317:given [Intellectual Product]
   714 E C1947971:Give [Functional Concept]
Processing 00000000.tx.76: Mean  SEM for 3 measurements are shown.  

Phrase: "Mean  SEM for 3 measurements"

Phrase: "are"

Phrase: "shown."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]
Processing 00000000.tx.77: No hematologic toxicity was observed in any of the patients and no abnormalities in kidney and liver function tests were noted (data not shown). 

Phrase: "No hematologic toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   861   C0040539:toxicity [Qualitative Concept]
   861   C0600688:Toxicity [Injury or Poisoning]
   789 E C1407029:Toxic [Qualitative Concept]
   768 E C0032346:Poison [Hazardous or Poisonous Substance]
   768 E C1548769:Poison [Intellectual Product]
   768 E C1550590:poison [Idea or Concept]

Phrase: "was"

Phrase: "observed in any of the patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0030705:Patients [Patient or Disabled Group]
   753   C1441672:Observed [Functional Concept]

Phrase: "and"

Phrase: "no abnormalities in kidney"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0000768:Abnormalities [Congenital Abnormality]
   770   C0000769:abnormalities [Functional Concept]
   737 E C1704258:Abnormality [Finding]

Phrase: "and"

Phrase: "liver function tests"
Meta Candidates (Total=17; Excluded=4; Pruned=0; Remaining=13)
  1000   C0023901:Liver Function Tests [Laboratory Procedure]
           liver tests
   901   C0232741:Liver function [Organ or Tissue Function]
   827   C0022885:Tests [Laboratory Procedure]
   827   C0023884:Liver [Body Part, Organ, or Organ Component]
   827   C0031843:function [Physiologic Function]
   827   C0392366:Tests [Intellectual Product]
   827   C0542341:Function [Functional Concept]
   827   C0700205:FUNCTION [Classification]
   827   C0736268:LIVER [Body Part, Organ, or Organ Component]
   827   C1278929:Liver [Body Part, Organ, or Organ Component]
   827   C1705273:Function [Intellectual Product]
   827   C2346688:LIVER [Food]
   793 E C0039593:Test [Functional Concept]
   771 E C0205054:Hepatic [Body Location or Region]
   755 E C0205245:Functional [Functional Concept]
   755 E C2700217:Functional [Conceptual Entity]

Phrase: "were"

Phrase: "noted"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.78: Patient MM-2 experienced transient dyspnea, weight on the chest, and shivering starting 2 hours following the sixth vaccination. 

Phrase: "Patient MM-2 experienced transient dyspnea,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0013404:Dyspnea [Sign or Symptom]

Phrase: "weight on the chest,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0005910:weight [Organism Attribute]
   770   C0043100:Weight [Quantitative Concept]
   770   C1305866:weight [Diagnostic Procedure]
   770   C1705104:Weight [Idea or Concept]

Phrase: "and"

Phrase: "shivering"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0036973:Shivering [Finding]
   928 E C0040822:Trembled [Sign or Symptom]
   928 E C0234369:Trembles [Sign or Symptom]

Phrase: "starting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0439659:Start [Temporal Concept]

Phrase: "2 hours"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1292425:2 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "the sixth vaccination."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0042196:Vaccination [Therapeutic or Preventive Procedure]
Processing 00000000.tx.79: The symptoms disappeared spontaneously within 1 hour. 

Phrase: "The symptoms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683368:symptoms [Functional Concept]
  1000   C1457887:Symptoms [Sign or Symptom]

Phrase: "disappeared"

Phrase: "spontaneously within 1 hour."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0439227:Hour [Temporal Concept]
   770   C0564385:/hour [Quantitative Concept]
Processing 00000000.tx.80: Patient MM-3 had fever (up to 38.5C) for about 24 hours after each vaccination and a National Cancer Institute (NCI) grade 2 local skin reaction. 

Phrase: "Patient MM-3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   812   C0030705:*^patient [Patient or Disabled Group]
   812   C0439064:Multiple [Quantitative Concept]
   812   C3538749:Myeloma [Intellectual Product]

Phrase: "had"

Phrase: "fever"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015967:Fever [Finding]

Phrase: "("

Phrase: "up to 38.5C"

Phrase: ")"

Phrase: "for about 24 hours"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   901   C0439584:24 hours [Temporal Concept]
   901   C0456696:/24 hours [Temporal Concept]
   901   C1442770:24 Hours [Temporal Concept]
   827   C0439227:hours [Temporal Concept]
   793 E C0564385:/hour [Quantitative Concept]

Phrase: "after each vaccination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "a National Cancer Institute (NCI) grade 2 local skin reaction."
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   864   C0007114:cancer skin [Neoplastic Process]
   822   C0853813:Local Reaction [Sign or Symptom]
   812   C0221743:Skin reaction [Clinical Attribute]
   793   C0443286:Reaction [Functional Concept]
   793   C0444099:Skin [Body Substance]
   793   C1114821:Reaction [Clinical Attribute]
   793   C1123023:Skin [Body System]
   793   C1278993:Skin [Body System]
   737 E C0221912:Cutaneous [Spatial Concept]
   737 E C0221928:Dermal [Qualitative Concept]
   737 E C1522447:Cutaneous [Functional Concept]
Processing 00000000.tx.81: Patient MM-4 had an NCI grade 2 local skin reaction at the first 5 vaccination times. 

Phrase: "Patient MM-4"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   812   C0030705:*^patient [Patient or Disabled Group]
   812   C0439064:Multiple [Quantitative Concept]
   812   C3538749:Myeloma [Intellectual Product]

Phrase: "had"

Phrase: "an NCI grade 2 local skin reaction"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   864   C0007114:cancer skin [Neoplastic Process]
   822   C0853813:Local Reaction [Sign or Symptom]
   812   C0221743:Skin reaction [Clinical Attribute]
   793   C0443286:Reaction [Functional Concept]
   793   C0444099:Skin [Body Substance]
   793   C1114821:Reaction [Clinical Attribute]
   793   C1123023:Skin [Body System]
   793   C1278993:Skin [Body System]
   737 E C0221912:Cutaneous [Spatial Concept]
   737 E C0221928:Dermal [Qualitative Concept]
   737 E C1522447:Cutaneous [Functional Concept]

Phrase: "at the first 5 vaccination times."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   812   C0040223:times [Temporal Concept]
   812   C1632851:Times [Quantitative Concept]
   779 E C3541383:Time [Temporal Concept]
   741 E C0442043:Temporal [Spatial Concept]
   741 E C2362314:Temporal [Temporal Concept]
Processing 00000000.tx.82: Patient MM-5 developed at the last vaccination petechial bleedings of the lower legs considered due to capillary leakage. 

Phrase: "Patient MM-5"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   812   C0030705:*^patient [Patient or Disabled Group]
   812   C0439064:Multiple [Quantitative Concept]
   812   C3538749:Myeloma [Intellectual Product]

Phrase: "developed at the last vaccination petechial bleedings of the lower legs"
Meta Candidates (Total=14; Excluded=6; Pruned=0; Remaining=8)
   756   C0230446:lower legs [Body Part, Organ, or Organ Component]
   738   C0042196:Vaccination [Therapeutic or Preventive Procedure]
   738   C0333284:Petechial [Functional Concept]
   738   C0441994:Lower [Spatial Concept]
   738   C1140621:Legs [Body Location or Region]
       E   Lower leg
   738   C1548802:Lower [Body Location or Region]
   738   C2003888:Lower [Activity]
   704   C0019080:Bleeding [Pathologic Function]
   704 E C0023216:Leg [Body Location or Region]
   704 E C0205251:low [Qualitative Concept]
   704 E C1285009:Leg [Body Location or Region]
   704 E C1299352:Low [Qualitative Concept]
   704 E C1550472:low [Idea or Concept]

Phrase: "considered due to capillary leakage."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   806   C0678226:Due to [Functional Concept]
           due
   760   C0006901:Capillary [Body Part, Organ, or Organ Component]
   760   C0015376:Leakage [Pathologic Function]
   760   C0750591:considered [Idea or Concept]
   760   C0935624:Capillary [Body Part, Organ, or Organ Component]
   760   C1280521:Capillary [Body Part, Organ, or Organ Component]
   760   C3146286:Due [Idea or Concept]
Processing 00000000.tx.83: One patient (MM-5) achieved a complete peripheral blood molecular remission (below 1:106, PCR negative using both ASO real-time and nested RT-PCR). 

Phrase: "One patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "(MM-5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: ")"

Phrase: "achieved"

Phrase: "a complete peripheral blood molecular remission"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   897   C0677874:Complete Remission [Finding]
   804   C0544452:Remission [Finding]
   804   C0687702:remission [Neoplastic Process]

Phrase: "("

Phrase: "below 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "106,"

Phrase: "PCR negative"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   812   C0205160:Negative [Qualitative Concept]
   812   C1513916:Negative [Finding]
   812   C2825415:Negative [Conceptual Entity]
   812   C2825491:Negative [Qualitative Concept]
   756   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "both ASO"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0002085:Allele [Gene or Genome]
   827   C0028953:Oligonucleotide [Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0205369:Specific [Qualitative Concept]
   827   C1552740:specific [Intellectual Product]

Phrase: "real-time"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C1550177:Real Time [Idea or Concept]
   861   C0040223:Time [Temporal Concept]
   861   C0237400:Real [Qualitative Concept]
   861   C3272377:REAL [Intellectual Product]
   861   C3541383:Time [Temporal Concept]
   805 E C0442043:Temporal [Spatial Concept]
   805 E C2362314:Temporal [Temporal Concept]
   777 E C1632851:Times [Quantitative Concept]

Phrase: "and"

Phrase: "nested RT-PCR"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   933   C0242574:Nested Polymerase Chain Reaction [Molecular Biology Research Technique]
   884   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   804   C0337112:Chain [Manufactured Object]
   804   C0443286:Reaction [Functional Concept]
   804   C1114821:Reaction [Clinical Attribute]
   804   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C1524075:Chain [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.84: Three patients had a reduction of 92%, 79%, and 54%, respectively, of the clonotypic B cells (MM-1, MM-3 and MM-2, respectively). 

Phrase: "Three patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "a reduction of 92%,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0301630:Reduction [Natural Phenomenon or Process]
   770   C0392756:Reduction [Qualitative Concept]
   770   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "79%,"

Phrase: "and"

Phrase: "54%,"

Phrase: "respectively,"

Phrase: "of the clonotypic B cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   901   C0004561:B-Cells [Cell]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "(MM-1,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "MM-3"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "and"

Phrase: "MM-2,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "respectively"

Phrase: ")."
Processing 00000000.tx.85: Two patients (MM-4 and MM-6) had unchanged levels of clonal B cells. 

Phrase: "Two patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(MM-4"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "and"

Phrase: "MM-6"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: ")"

Phrase: "had"

Phrase: "unchanged levels of clonal B cells."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.86: In no patient was a significant change of the serum M-component concentration observed during the study period (Table 2). 

Phrase: "In no patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "a significant change of the serum M-component concentration"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0392747:Change [Functional Concept]
   742   C0443172:change [Quantitative Concept]
   742   C1705241:Change [Quantitative Concept]

Phrase: "observed during the study period"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0439531:/period [Temporal Concept]
   760   C0557651:Study [Manufactured Object]
   760   C1441672:Observed [Functional Concept]
   760   C1948053:Period [Temporal Concept]
   760   C2603343:Study [Research Activity]

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.87: View this table: [in this window] [in a new window]  Table 2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.88: Id-specific T-cell response (proliferation/cytokine production) and M-component concentration in myeloma patients immunized with the autologous tumor-derived Id Ig in combination with adjuvant cytokines  Patients MM-1, MM-2, MM-4, and MM-5 mounted an Idspecific T-cell response, whereas in patients MM-3 and MM-6 no Id-specific T-cell response was detected (Table 2). 

Phrase: "Id-specific T-cell response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0871261:Response [Organism Attribute]
   804   C1704632:Response [Finding]
   804   C1706817:Response [Intellectual Product]
   804   C2911692:Response [Mental Process]

Phrase: "(proliferation/cytokine production"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1327413:cytokine production [Organism Function]
   827   C0033268:production [Occupational Activity]

Phrase: ")"

Phrase: "and"

Phrase: "M-component concentration in myeloma patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0086045:Concentration [Mental Process]
   753   C1446561:Concentration [Quantitative Concept]

Phrase: "immunized with the autologous tumor-derived Id Ig"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   770   C1519667:Tumor-Derived [Functional Concept]
   767   C0021013:Immunoglobulin idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Idiotype
   744   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   744   C0027651:Tumor [Neoplastic Process]
   744   C0439859:Autologous [Qualitative Concept]
   744   C1441547:Derived [Qualitative Concept]
   744   C1578706:Tumor [Intellectual Product]
   744   C1621846:immunoglobulin [Molecular Function]
   744   C3245521:derived [Idea or Concept]
   744   C3273930:Tumor [Finding]

Phrase: "in combination"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205195:Combination [Qualitative Concept]
  1000   C1947911:Combination [Physical Object]

Phrase: "with adjuvant cytokines  Patients MM-1,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   827   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   799   C0001551:Adjuvant, NOS [Immunologic Factor,Pharmacologic Substance]
   799   C0001552:Adjuvant [Chemical Viewed Functionally]
   799   C0030705:Patients [Patient or Disabled Group]
   799   C0079189:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor]
   799   C0439064:Multiple [Quantitative Concept]
   799   C1522673:Adjuvant [Functional Concept]
   799   C1524094:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   799   C3538749:Myeloma [Intellectual Product]

Phrase: "MM-2,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "MM-4,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "and"

Phrase: "MM-5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "mounted"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0449878:mounted [Finding]
   966 E C0181909:Mount [Medical Device]

Phrase: "an Idspecific T-cell response,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0871261:Response [Organism Attribute]
   812   C1704632:Response [Finding]
   812   C1706817:Response [Intellectual Product]
   812   C2911692:Response [Mental Process]

Phrase: "whereas in patients MM-3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0439064:Multiple [Quantitative Concept]
   753   C3538749:Myeloma [Intellectual Product]

Phrase: "and"

Phrase: "MM-6"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "no Id-specific T-cell response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0871261:Response [Organism Attribute]
   804   C1704632:Response [Finding]
   804   C1706817:Response [Intellectual Product]
   804   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "detected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0442726:Detected [Finding]
  1000   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.89: Thus, 3 patients mounting an Id-specific T-cell response had tumor cell reduction, whereas one patient developing an anti-Id cellular response showed no decrease in circulating tumor B cells. 

Phrase: "Thus,"

Phrase: "3 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "mounting"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0181909:Mount [Medical Device]
   966   C0449878:mount [Finding]

Phrase: "an Id-specific T-cell response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0871261:Response [Organism Attribute]
   804   C1704632:Response [Finding]
   804   C1706817:Response [Intellectual Product]
   804   C2911692:Response [Mental Process]

Phrase: "had"

Phrase: "tumor cell reduction,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0301630:Reduction [Natural Phenomenon or Process]
   827   C0392756:Reduction [Qualitative Concept]
   827   C0441610:Reduction [Therapeutic or Preventive Procedure]
   734   C0431085:Tumor cell [Cell]
   734   C0597032:Tumor Cell [Cell]

Phrase: "whereas"

Phrase: "one patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "developing"

Phrase: "an anti-Id cellular response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0871261:Response [Organism Attribute]
   812   C1704632:Response [Finding]
   812   C1706817:Response [Intellectual Product]
   812   C2911692:Response [Mental Process]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "no decrease in circulating tumor B cells."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0392756:Decrease [Qualitative Concept]
   748   C0547047:Decrease [Quantitative Concept]
Processing 00000000.tx.90: However, one patient (MM-3) had a tumor mass reduction without a detectable T-cell response. 

Phrase: "However,"

Phrase: "one patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "(MM-3"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: ")"

Phrase: "had"

Phrase: "a tumor mass reduction without a detectable T-cell response."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   739   C0301630:Reduction [Natural Phenomenon or Process]
   739   C0392756:Reduction [Qualitative Concept]
   739   C0441610:Reduction [Therapeutic or Preventive Procedure]
Processing 00000000.tx.91: A similar phenomenon has been described in melanoma patients immunized with MAGE-3 peptides. 

Phrase: "A similar phenomenon"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1882365:Phenomenon [Phenomenon or Process]

Phrase: "has"

Phrase: "been"

Phrase: "described in melanoma patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0025202:melanoma [Neoplastic Process]
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1552738:described [Idea or Concept]
   770   C2984289:Melanoma [Functional Concept]
   770   C3539018:Melanoma [Intellectual Product]

Phrase: "immunized with MAGE-3 peptides."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0030956:Peptides [Amino Acid, Peptide, or Protein]
   760   C1709015:MAGE [Organization]
Processing 00000000.tx.92: Partial and complete remissions were obtained without detectable MAGE-3specific T cells.16 Massaia and coworkers17 immunized 2 MM patients with minimal residual disease using the Id but were not able to detect a reduction of circulating tumor cells by PCR. 

Phrase: "Partial"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0728938:Partial [Quantitative Concept]
  1000   C1550516:partial [Idea or Concept]

Phrase: "and"

Phrase: "complete remissions"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   966   C0677874:Complete Remission [Finding]
   861   C0205197:Complete [Qualitative Concept]
   861   C0544452:remissions [Finding]
   861   C0687702:remissions [Neoplastic Process]
   861   C0725685:COMPLEAT [Food]
   789 E C0439812:Completeness [Qualitative Concept]

Phrase: "were"

Phrase: "obtained without detectable MAGE-3specific T cells.16 Massaia"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   764   C0039194:T-Cells [Cell]
   742   C0007634:Cells [Cell]
   742   C1301820:Obtained [Functional Concept]
   742   C1709015:MAGE [Organization]
   742   C3282337:Cells [Cell]
   708 E C1269647:Cell [Cell]
   708 E C1704653:Cell [Medical Device]
   708 E C1706701:Obtain [Activity]
   708 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "coworkers17"

Phrase: "immunized"

Phrase: "2 MM patients with minimal residual disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0030705:Patients [Patient or Disabled Group]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the Id"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021013:Idiotype [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "but"

Phrase: "were"

Phrase: "not able to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0085732:Able [Organism Attribute]
   827   C1299581:Able [Finding]
   827   C1518422:Not [Functional Concept]

Phrase: "detect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442726:detect [Finding]

Phrase: "a reduction of circulating tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "by PCR."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]
Processing 00000000.tx.93: The reason for the discrepancy is not clear but may be due to the small number of patients, a different vaccination schedule, and the fact that the patients probably exhibited a pronounced T-cell dysfunction due to high-dose chemotherapy. 

Phrase: "The reason for the discrepancy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0392360:Reason [Idea or Concept]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "clear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2963144:Clear [Qualitative Concept]

Phrase: "but"

Phrase: "may"

Phrase: "be due to the small number of patients,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   800   C2360800:Number of patients [Finding]
   770   C0678226:Due to [Functional Concept]
           due
   750   C1830427:Patient number [Intellectual Product]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0237753:*Number [Quantitative Concept]
   744   C0449788:Number [Quantitative Concept]
   744   C0700321:Small [Quantitative Concept]
   744   C2987476:Be [Conceptual Entity]
   744   C3146286:Due [Idea or Concept]

Phrase: "a different vaccination schedule,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0086960:Schedule [Intellectual Product]

Phrase: "and"

Phrase: "the fact"

Phrase: "that"

Phrase: "the patients probably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "exhibited"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0015272:Exhibit [Intellectual Product]

Phrase: "a pronounced T-cell dysfunction due to high-dose chemotherapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   782   C3277427:T-cell dysfunction [Finding]
   739   C0031847:dysfunction [Functional Concept]
   739   C0277785:Dysfunction, NOS [Qualitative Concept]
Processing 00000000.tx.94: Moreover, in that study GM-CSF or IL-2 was used as an adjuvant cytokine, whereas all our patients received IL-12. 

Phrase: "Moreover,"

Phrase: "in"

Phrase: "that study GM-CSF"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   947   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
   947   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   947   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
   947   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   901   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   861   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0018183:granulocyte [Cell]
   799   C0024432:macrophage [Cell]
   799   C0439158:colony [Quantitative Concept]
   799   C1521761:Factor [Functional Concept]
   799   C1947989:Colony [Cell]
   799   C1948023:Stimulating [Natural Phenomenon or Process]
   799   C2827422:Factor [Conceptual Entity]

Phrase: "or"

Phrase: "IL-2"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0021756:IL2 [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0879590:IL2 [Gene or Genome]
   861   C0020898:IL [Geographic Area]
   861   C0021764:IL [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0022271:IL [Geographic Area]

Phrase: "was"

Phrase: "used as an adjuvant cytokine,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   760   C0001551:Adjuvant, NOS [Immunologic Factor,Pharmacologic Substance]
   760   C0001552:Adjuvant [Chemical Viewed Functionally]
   760   C0079189:cytokine [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C1273517:used [Finding]
   760   C1522673:Adjuvant [Functional Concept]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726 E C1947944:Use [Intellectual Product]

Phrase: "whereas"

Phrase: "all our patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "IL-12."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.95: It was recently shown in an animal model that immunization with myeloma cells transfected both with the GM-CSF and IL-12 genes induced proliferative as well as cytotoxic T-cell responses directed against the secreted monoclonal Ig and protected more than 90% of the animals against tumor challenge.18 It is not likely that IL-12 alone contributed to the blood tumor cell reduction observed in our patient because the adjuvant dose of IL-12 was very low; 

Phrase: "It"

Phrase: "was"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "shown in an animal model"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0599779:Animal Model [Animal]
   760   C0003062:Animal [Animal]
   760   C3161035:Model [Intellectual Product]
   726   C1547282:Show [Intellectual Product]

Phrase: "that immunization with myeloma cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0020971:Immunisation [Therapeutic or Preventive Procedure]
   760   C0042196:immunisation [Therapeutic or Preventive Procedure]
   760   C3244291:immunization [Functional Concept]

Phrase: "transfected"

Phrase: "both with the GM-CSF"
Meta Candidates (Total=18; Excluded=0; Pruned=0; Remaining=18)
   869   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
   869   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   869   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
   869   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   833   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   833   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   822   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   800   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0018183:granulocyte [Cell]
   744   C0024432:macrophage [Cell]
   744   C0238767:Both [Spatial Concept]
   744   C0439158:colony [Quantitative Concept]
   744   C1521761:Factor [Functional Concept]
   744   C1706086:Both [Qualitative Concept]
   744   C1947989:Colony [Cell]
   744   C1948023:Stimulating [Natural Phenomenon or Process]
   744   C2827422:Factor [Conceptual Entity]

Phrase: "and"

Phrase: "IL-12 genes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   983   C0879338:interleukin-12 gene [Gene or Genome]
   896   C1334205:Interleukin Gene [Gene or Genome]
   827   C0017337:Genes [Gene or Genome]
   734   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   734   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "proliferative"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0334094:Proliferative [Pathologic Function]

Phrase: "as well as"

Phrase: "cytotoxic T-cell responses"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   812   C0871261:responses [Organism Attribute]
   779 E C1704632:Response [Finding]
   779 E C1706817:Response [Intellectual Product]
   779 E C2911692:Response [Mental Process]
   756   C0039195:Cytotoxic T cell [Cell]
   708   C0022686:Cytotoxic cell [Cell]

Phrase: "directed against the secreted monoclonal Ig"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0443737:Monoclonal immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   790   C0700271:Monoclonal immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   753   C0746619:monoclonal [Finding]
   753   C1327616:Secreted [Cell Function]
   753   C1621846:immunoglobulin [Molecular Function]
   719   C0439851:Direct [Qualitative Concept]
   719   C1947931:Direct [Qualitative Concept]

Phrase: "and"

Phrase: "protected"

Phrase: "more than 90% of the animals"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0003062:Animals [Animal]
   753   C0205172:More [Functional Concept]
   753   C0439083:>90 [Quantitative Concept]
   753   C0439087:<90 [Quantitative Concept]

Phrase: "against tumor challenge.18"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0027651:Tumor [Neoplastic Process]
   827   C0798503:Challenge [Clinical Attribute]
   827   C0805586:Challenge [Health Care Activity]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3274764:Challenge [Conceptual Entity]

Phrase: "It"

Phrase: "is"

Phrase: "not likely"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]
   861   C1518422:Not [Functional Concept]

Phrase: "that IL-12"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0123759:Interleukin-12 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1524115:Interleukin 12 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "contributed to the blood tumor cell reduction"
Meta Candidates (Total=20; Excluded=1; Pruned=0; Remaining=19)
   778   C0431085:Tumor cell [Cell]
   778   C0597032:Tumor Cell [Cell]
   774   C0005773:Blood cell [Cell]
   748   C0005767:Blood [Tissue]
   748   C0005768:blood [Body Substance]
   748   C0007634:Cell [Cell]
   748   C0027651:Tumor [Neoplastic Process]
   748   C0229664:Blood [Body Substance]
   748   C0301630:Reduction [Natural Phenomenon or Process]
   748   C0392756:Reduction [Qualitative Concept]
   748   C0441610:Reduction [Therapeutic or Preventive Procedure]
   748   C1269647:Cell [Cell]
   748   C1578706:Tumor [Intellectual Product]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]
   748   C3273930:Tumor [Finding]
   746 E C2328697:Hemal cell [Cell]
   737   C0027668:Tumor, Blood Vessel [Neoplastic Process]
   737   C0282607:Blood vessel tumor [Neoplastic Process]
   714   C1880177:Contribute [Activity]

Phrase: "observed in our patient"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0030705:*^patient [Patient or Disabled Group]
   770   C1441672:Observed [Functional Concept]

Phrase: "because"

Phrase: "the adjuvant dose of IL-12"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0178602:Dose [Quantitative Concept]
   753   C0869039:Dose [Quantitative Concept]
   753   C1114758:Dose # [Clinical Attribute]

Phrase: "was"

Phrase: "very low"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0442811:Very low [Finding]
   861   C0205251:low [Qualitative Concept]
   861   C1299352:Low [Qualitative Concept]
   861   C1550472:low [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.96: only 1% of the dose used for treatment of patients with malignancies. 

Phrase: "only 1% of the dose"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0178602:Dose [Quantitative Concept]
   760   C0205171:Only [Quantitative Concept]
   760   C0869039:Dose [Quantitative Concept]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1720467:Only [Intellectual Product]

Phrase: "used for treatment of patients"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   781   C1524063:Use of [Functional Concept]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1273517:used [Finding]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726 E C1947944:Use [Intellectual Product]

Phrase: "with malignancies."
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0006826:MALIGNANCIES [Neoplastic Process]
   966 E C1306459:Malignancy [Finding]
   916 E C0205282:Malignant [Qualitative Concept]
   916 E C0334590:MALIGNANT [Neoplastic Process]
   916 E C1533592:MALIGNANT [Neoplastic Process]
Processing 00000000.tx.97: However, in our patients no major tumor reduction was noted, as measured by serum M-component concentration, which was stable over time in all patients, indicating that myeloma-specific T cells might only be able to eradicate a minimal tumor burden. 

Phrase: "However,"

Phrase: "in our patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "no major tumor reduction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0301630:Reduction [Natural Phenomenon or Process]
   827   C0392756:Reduction [Qualitative Concept]
   827   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "noted"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]

Phrase: ","

Phrase: "as"

Phrase: "measured by serum M-component concentration,"
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   790   C0030490:M component [Amino Acid, Peptide, or Protein,Immunologic Factor]
   783   C0683149:concentration serum [Quantitative Concept]
   753   C0086045:Concentration [Mental Process]
   753   C0229671:Serum [Body Substance]
   753   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0441923:M+ [Intellectual Product]
   753   C0444706:Measured [Qualitative Concept]
   753   C0449432:Component [Manufactured Object]
   753   C1446561:Concentration [Quantitative Concept]
   753   C1546774:Serum [Intellectual Product]
   753   C1550100:Serum [Body Substance]
   753   C1705248:Component [Conceptual Entity]
   753   C3541902:MEASURED [Diagnostic Procedure]
   719 E C0079809:Measure [Quantitative Concept]
   719 E C0242485:Measure [Functional Concept]

Phrase: "which"

Phrase: "was"

Phrase: "stable over time"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205360:Stable [Qualitative Concept]
   790   C1547311:Stable [Intellectual Product]

Phrase: "in all patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "indicating"

Phrase: "that myeloma-specific T cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   886   C0333843:Myeloma cell [Cell]
   861   C0039194:T-Cells [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: "might"

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "be"

Phrase: "able to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0085732:Able [Organism Attribute]
   861   C1299581:Able [Finding]

Phrase: "eradicate"

Phrase: "a minimal tumor burden."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1449699:Tumor Burden [Diagnostic Procedure]
   827   C2828008:Burden [Idea or Concept]
Processing 00000000.tx.98: This is the first study in myeloma showing that Id immunization is able to induce reduction at the molecular level of circulating tumor cells similar to the observation in follicular lymphomas where immunotherapy could induce molecular remission after chemotherapy induced clinical remission using Id vaccination7 as well as monoclonal antibody therapy (rituximab).19 In conclusion, Id vaccination in patients with MM may induce tumor-specific T cells that might target circulating clonal tumor B cells. 

Phrase: "This"

Phrase: "is"

Phrase: "the first study in myeloma"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0557651:Study [Manufactured Object]
   760   C2603343:Study [Research Activity]

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that Id immunization"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0020971:Immunisation [Therapeutic or Preventive Procedure]
   861   C0042196:immunisation [Therapeutic or Preventive Procedure]
   861   C3244291:immunization [Functional Concept]

Phrase: "is"

Phrase: "able to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0085732:Able [Organism Attribute]
   861   C1299581:Able [Finding]

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "reduction at the molecular level of circulating tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0301630:Reduction [Natural Phenomenon or Process]
   742   C0392756:Reduction [Qualitative Concept]
   742   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "similar to the observation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2348205:Similar [Qualitative Concept]

Phrase: "in follicular lymphomas where immunotherapy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0021083:Immunotherapy [Therapeutic or Preventive Procedure]

Phrase: "could"

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "molecular remission after chemotherapy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0544452:Remission [Finding]
   770   C0687702:remission [Neoplastic Process]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "clinical remission"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205210:Clinical [Qualitative Concept]
   861   C0544452:Remission [Finding]
   861   C0687702:remission [Neoplastic Process]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "Id vaccination7"

Phrase: "as well as"

Phrase: "monoclonal antibody therapy"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0279694:Monoclonal Antibody Therapy [Therapeutic or Preventive Procedure]
   901   C0281176:antibody therapy [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]
   734   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "(rituximab"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0393022:rituximab [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: ").19 In conclusion,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707478:Conclusion [Idea or Concept]

Phrase: "Id vaccination in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "with MM"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "may"

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "tumor-specific T cells"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   902   C0431085:Tumor cells [Cell]
   886 E C0597032:Tumor Cell [Cell]
   861   C0039194:T-Cells [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: "that"

Phrase: "might"

Phrase: "target"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1521840:Target [Functional Concept]
  1000   C2986546:TARGET [Diagnostic Procedure]

Phrase: "circulating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0175630:Circulating [Functional Concept]

Phrase: "clonal tumor B cells."
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   875   C0431085:Tumor cells [Cell]
   867   C0009013:Clone Cells [Cell]
   861   C0004561:B-Cells [Cell]
   858 E C0597032:Tumor Cell [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.99: Id vaccination may preferentially be applied when the tumor load is low, that is, early during the course of the disease or after chemotherapy. 

Phrase: "Id vaccination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "may"

Phrase: "preferentially"

Phrase: "be"

Phrase: "applied"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0185125:Applied [Health Care Activity]
   966 E C1632850:Apply [Functional Concept]
   966 E C1879355:Apply [Functional Concept]

Phrase: "when"

Phrase: "the tumor load"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1449699:Tumor Load [Diagnostic Procedure]
   861   C1550025:Load [Idea or Concept]
   861   C1704782:Load [Manufactured Object]
   861   C1708715:Load [Activity]

Phrase: "is"

Phrase: "low,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205251:low [Qualitative Concept]
  1000   C1299352:Low [Qualitative Concept]
  1000   C1550472:low [Idea or Concept]

Phrase: "that"

Phrase: "is"

Phrase: ","

Phrase: "early during the course of the disease"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   774   C0242656:disease course [Pathologic Function]
   774   C0679245:early disease [Temporal Concept]
   748   C0012634:Disease [Disease or Syndrome]
   748   C0750729:Course [Temporal Concept]
   748   C1279919:Early [Temporal Concept]

Phrase: "or after chemotherapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   790   C0013217:chemotherapy [Functional Concept]
   790   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
Processing 00000000.tx.100: In the latter case measures should be taken to augment T-cell functions because otherwise an effective tumorspecific immune response may not be induced.  

Phrase: "In the latter case measures"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0079809:Measures [Quantitative Concept]
   827   C1879489:Measures [Functional Concept]
   793 E C0242485:Measure [Functional Concept]

Phrase: "should"

Phrase: "be"

Phrase: "taken"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883727:Taken [Conceptual Entity]
   966 E C1515187:Take [Health Care Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "augment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205217:augment [Quantitative Concept]

Phrase: "T-cell functions"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   901   C0007613:cell functions [Cell Function]
   901   C0039194:T-cell [Cell]
   827   C0007634:Cell [Cell]
   827   C0542341:Functions [Functional Concept]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
   793 E C0031843:function [Physiologic Function]
   793 E C0700205:FUNCTION [Classification]
   793 E C1705273:Function [Intellectual Product]
   743 E C0205245:Functional [Functional Concept]
   743 E C2700217:Functional [Conceptual Entity]

Phrase: "because"

Phrase: "otherwise"

Phrase: "an effective tumorspecific immune response"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0301872:Immune response [Organ or Tissue Function]
   812   C0439662:Immune [Functional Concept]
   812   C0871261:Response [Organism Attribute]
   812   C1704632:Response [Finding]
   812   C1706817:Response [Intellectual Product]
   812   C2911692:Response [Mental Process]

Phrase: "may"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "be"

Phrase: "induced."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]
Processing 00000000.tx.101: Acknowledgements  We thank Lone Honor and Ingrid Eriksson for technical assistance.  

Phrase: "Acknowledgements"

Phrase: "We"

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Lone Honor"

Phrase: "and"

Phrase: "Ingrid Eriksson for technical assistance."
Processing 00000000.tx.102: Footnotes  Submitted July 11, 2002; 

Phrase: "Footnotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2825232:Footnote [Intellectual Product]

Phrase: "Submitted July 11,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1515023:Submitted [Functional Concept]

Phrase: "2002"

Phrase: ";"
Processing 00000000.tx.103: accepted January 23, 2003. 

Phrase: "accepted January 23,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0450348:23 [Quantitative Concept]
   827   C1272684:Accepted [Qualitative Concept]
   827   C1548435:Accepted [Idea or Concept]

Phrase: "2003."
Processing 00000000.tx.104: Prepublished online as Blood First Edition Paper, February 6, 2003; 

Phrase: "Prepublished online as Blood First Edition Paper,"

Phrase: "February 6,"

Phrase: "2003"

Phrase: ";"
Processing 00000000.tx.105: DOI 10.1182/blood-2002-06-1925. 

Phrase: "DOI 10.1182/blood-2002-06-1925."
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   795   C0005767:Blood [Tissue]
   795   C0005768:blood [Body Substance]
   795   C0229664:Blood [Body Substance]
   795   C2348291:DOI [Classification]
   724 E C0333275:Bloody [Qualitative Concept]
   712 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   712 E C0392895:Bloods [Population Group]
   712 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   712 E C1511228:VESSEL, BLOOD [Tissue]
Processing 00000000.tx.106: Supported in part by the Hans Edstrand Foundation, Danish Cancer Society, Swedish Cancer Society, Cancer Society of Stockholm, Torsten and Ragnar Sderbergs Foundation, Cancer Allergy Foundation, Hedberg Foundation, International Myeloma Foundation, and Multiple Myeloma Research Foundation. 

Phrase: "Supported in part"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0449719:Part [Spatial Concept]
   790   C1521721:Supported [Conceptual Entity]
   790   C1709471:Part [Quantitative Concept]
   756 E C0183683:Support [Medical Device]

Phrase: "by the Hans Edstrand Foundation,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   827   C0016617:Foundation [Organization]
   743 E C0002055:base [Inorganic Chemical]
   743 E C0178499:Base [Chemical Viewed Functionally]
   743 E C1626935:Bases [Quantitative Concept]
   743 E C1880279:Base [Biomedical or Dental Material]
   721 E C0205112:Basal [Spatial Concept]

Phrase: "Danish Cancer Society,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0037455:society [Organization]

Phrase: "Swedish Cancer Society,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0037455:society [Organization]

Phrase: "Cancer Society of Stockholm,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0037455:society [Organization]

Phrase: "Torsten"

Phrase: "and"

Phrase: "Ragnar Sderbergs Foundation,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   827   C0016617:Foundation [Organization]
   743 E C0002055:base [Inorganic Chemical]
   743 E C0178499:Base [Chemical Viewed Functionally]
   743 E C1626935:Bases [Quantitative Concept]
   743 E C1880279:Base [Biomedical or Dental Material]
   721 E C0205112:Basal [Spatial Concept]

Phrase: "Cancer Allergy Foundation,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   827   C0016617:Foundation [Organization]
   743 E C0002055:base [Inorganic Chemical]
   743 E C0178499:Base [Chemical Viewed Functionally]
   743 E C1626935:Bases [Quantitative Concept]
   743 E C1880279:Base [Biomedical or Dental Material]
   721 E C0205112:Basal [Spatial Concept]

Phrase: "Hedberg Foundation,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0016617:Foundation [Organization]
   777 E C0002055:base [Inorganic Chemical]
   777 E C0178499:Base [Chemical Viewed Functionally]
   777 E C1626935:Bases [Quantitative Concept]
   777 E C1880279:Base [Biomedical or Dental Material]
   755 E C0205112:Basal [Spatial Concept]

Phrase: "International Myeloma Foundation,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   827   C0016617:Foundation [Organization]
   743 E C0002055:base [Inorganic Chemical]
   743 E C0178499:Base [Chemical Viewed Functionally]
   743 E C1626935:Bases [Quantitative Concept]
   743 E C1880279:Base [Biomedical or Dental Material]
   721 E C0205112:Basal [Spatial Concept]

Phrase: "and"

Phrase: "Multiple Myeloma Research Foundation."
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
   819   C2986512:Research Base [Organization]
   812   C0016617:Foundation [Organization]
   729 E C0002055:base [Inorganic Chemical]
   729 E C0178499:Base [Chemical Viewed Functionally]
   729 E C1626935:Bases [Quantitative Concept]
   729 E C1880279:Base [Biomedical or Dental Material]
   706 E C0205112:Basal [Spatial Concept]
Processing 00000000.tx.107: T.R. and L.H. contributed equally to this study. 

Phrase: "T.R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "and"

Phrase: "L.H."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2346686:L/h [Quantitative Concept]
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "contributed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1880177:Contribute [Activity]

Phrase: "equally to this study."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]
Processing 00000000.tx.108: The publication costs of this article were defrayed in part by page charge payment. 

Phrase: "The publication"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0034036:Publication [Intellectual Product,Manufactured Object]
  1000   C0034037:Publication [Occupational Activity]
  1000   C1704324:Publication [Intellectual Product]

Phrase: "costs of this article"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0010186:Cost [Quantitative Concept]
   770   C0220812:Costs [Quantitative Concept]
   770   C1706852:Article [Intellectual Product]

Phrase: "were"

Phrase: "defrayed in part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0449719:Part [Spatial Concept]
   790   C1709471:Part [Quantitative Concept]

Phrase: "by page charge payment."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0220808:payment [Quantitative Concept]
   827   C0680264:payment [Quantitative Concept]
Processing 00000000.tx.109: Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. 

Phrase: "Therefore,"

Phrase: "and"

Phrase: "solely to"

Phrase: "indicate"

Phrase: "this fact,"

Phrase: "this article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "is"

Phrase: "hereby"

Phrase: "marked"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0522501:Marked [Qualitative Concept]
  1000   C1706089:Marked [Qualitative Concept]

Phrase: """advertisement"""
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0949214:advertisement [Intellectual Product]

Phrase: "in accordance with 18 U.S.C. section 1734."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0041703:U S [Geographic Area]
   799   C0205155:Section [Spatial Concept]
   799   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   799   C1522472:Section [Substance]
   799   C1552923:Section [Quantitative Concept]
   799   C1705191:Section [Physical Object]
Processing 00000000.tx.110: Reprints: Hkan Mellstedt, Department of Oncology (Radiumhemmet), Karolinska Hospital, SE-171 76 Stockholm, Sweden; 

Phrase: "Reprints"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C3273171:Reprint [Intellectual Product]

Phrase: ":"

Phrase: "Hkan Mellstedt,"

Phrase: "Department of Oncology"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1704729:Department [Organization]

Phrase: "(Radiumhemmet"

Phrase: ")"

Phrase: ","

Phrase: "Karolinska Hospital,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   861   C1510665:Hospital [Qualitative Concept]
   777 E C1609061:Hospitals [Intellectual Product]

Phrase: "SE-171 76 Stockholm,"

Phrase: "Sweden"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038995:Sweden [Geographic Area]

Phrase: ";"
Processing 00000000.tx.111: e-mail: hakan.mellstedt{at}ks.se .  References Top Abstract Introduction Study design Results and discussion References  Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. 

Phrase: "e-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "hakan.mellstedt{at}ks.se ."

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Top Abstract Introduction Study design Results"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   839   C0683954:study results [Finding]
   766   C1274040:Result [Functional Concept]
   766   C1546471:Result [Idea or Concept]
   766   C2825142:Result [Finding]

Phrase: "and"

Phrase: "discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557061:Discussion [Therapeutic or Preventive Procedure]
  1000   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Yi Q,"

Phrase: "Osterborg A,"

Phrase: "Bergenbrant S,"

Phrase: "Mellstedt H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Holm G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Lefvert AK."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0001905:AK [Geographic Area]
   861   C1412243:AK [Gene or Genome]
Processing 00000000.tx.112: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. 

Phrase: "Idiotype-reactive T-cell subsets"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   884   C0080202:T-Cell Subsets [Cell]
   884   C2362651:T cell subsets [Finding]
   771   C1515021:Subset [Classification]

Phrase: "and"

Phrase: "tumor load in monoclonal gammopathies."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1449699:Tumor Load [Diagnostic Procedure]
   760   C1550025:Load [Idea or Concept]
   760   C1704782:Load [Manufactured Object]
   760   C1708715:Load [Activity]
Processing 00000000.tx.113: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.114: 1995;86: 3043-3049.[Abstract/Free FullText] Li Y, Bendandi M, Deng Y, et al. 

Phrase: "1995"

Phrase: ";86"

Phrase: ":"

Phrase: "3043-3049."

Phrase: "[Abstract/Free FullText"

Phrase: "] Li Y,"

Phrase: "Bendandi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Deng Y,"

Phrase: "et al."
Processing 00000000.tx.115: Tumor-specific recognition of human myeloma cells by idiotypeinduced CD8(+) T cells. 

Phrase: "Tumor-specific recognition of human myeloma cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C0678836:cell recognition [Cell Function]
   748   C0524637:Recognition [Mental Process]

Phrase: "by idiotypeinduced CD8"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C3538720:CD8 [Laboratory Procedure]
   861   C3540595:CD8 [Gene or Genome]

Phrase: "(+"

Phrase: ")"

Phrase: "T cells."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0039194:T-Cells [Cell]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.116: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.117: 2000;96: 2828-2833.[Abstract/Free FullText] Wen YJ, Barlogie B, Yi Q. 

Phrase: "2000"

Phrase: ";96"

Phrase: ":"

Phrase: "2828-2833."

Phrase: "[Abstract/Free FullText"

Phrase: "] Wen YJ,"

Phrase: "Barlogie B,"

Phrase: "Yi Q."
Processing 00000000.tx.118: Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. 

Phrase: "Idiotype-specific cytotoxic T lymphocytes in multiple myeloma"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   800   C0039195:Cytotoxic T-Lymphocytes [Cell]
   770   C0039194:T-Lymphocytes [Cell]
   744   C0024264:Lymphocytes [Cell]
   744   C0677881:Cytotoxic [Therapeutic or Preventive Procedure]
   744   C1511636:cytotoxic [Functional Concept]

Phrase: ":"

Phrase: "evidence for their capacity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0332120:Evidence [Functional Concept]

Phrase: "to"

Phrase: "lyse"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024348:lyse [Pathologic Function]

Phrase: "autologous primary tumor cells."
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   923   C1510985:Autologous Tumor Cells [Cell]
   861   C0431085:Tumor cells [Cell]
   827 E C0597032:Tumor Cell [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.119: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.120: 2001;97: 1750-1755.[Abstract/Free FullText] Osterborg A, Yi Q, Henriksson L, et al. 

Phrase: "2001"

Phrase: ";97"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439073:97 [Intellectual Product]
  1000   C0439082:>97 [Quantitative Concept]

Phrase: ":"

Phrase: "1750-1755."

Phrase: "[Abstract/Free FullText"

Phrase: "] Osterborg A,"

Phrase: "Yi Q,"

Phrase: "Henriksson L,"

Phrase: "et al."
Processing 00000000.tx.121: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. 

Phrase: "Idiotype immunization"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0020971:Immunisation [Therapeutic or Preventive Procedure]
   861   C0042196:immunisation [Therapeutic or Preventive Procedure]
   861   C3244291:immunization [Functional Concept]

Phrase: "combined with granulocyte-macrophage colony-stimulating factor"
Meta Candidates (Total=18; Excluded=1; Pruned=0; Remaining=17)
   897   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
   897   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   897   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
   897   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   853   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   853   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   840   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   814   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0018183:granulocyte [Cell]
   748   C0024432:macrophage [Cell]
   748   C0205195:Combined [Qualitative Concept]
   748   C0439158:colony [Quantitative Concept]
   748   C1521761:Factor [Functional Concept]
   748   C1947989:Colony [Cell]
   748   C1948023:Stimulating [Natural Phenomenon or Process]
   748   C2827422:Factor [Conceptual Entity]
   714 E C0336789:Combine [Manufactured Object]

Phrase: "in myeloma patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "type I,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441729:Type I [Classification]
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "major histocompatibility complex-restricted, CD8-"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C3538720:CD8 [Laboratory Procedure]
   804   C3540595:CD8 [Gene or Genome]
   717   C0024518:Major Histocompatibility Complex [Gene or Genome]
   717   C1753349:Major histocompatibility complex [Cell Component]

Phrase: "and"

Phrase: "CD4-specific T-cell responses."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   804   C0871261:responses [Organism Attribute]
   771 E C1704632:Response [Finding]
   771 E C1706817:Response [Intellectual Product]
   771 E C2911692:Response [Mental Process]
   708   C0039215:cd4 cell [Cell]
   708   C3251824:CD4+ cell [Cell]
Processing 00000000.tx.122: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.123: 1998;91: 2459-2466.[Abstract/Free FullText] Lynch RG, Graff RJ, Sirisinha S, Simms E, Eisen NH. 

Phrase: "1998"

Phrase: ";91"

Phrase: ":"

Phrase: "2459-2466."

Phrase: "[Abstract/Free FullText"

Phrase: "] Lynch RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "Graff RJ,"

Phrase: "Sirisinha S,"

Phrase: "Simms E,"

Phrase: "Eisen NH."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0268059:NH [Disease or Syndrome]
Processing 00000000.tx.124: Myeloma proteins as tumor specific transplantation antigens. 

Phrase: "Myeloma proteins as tumor specific transplantation antigens."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0027015:Myeloma Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   774   C0260034:Tumor proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0026764:Myeloma [Neoplastic Process]
   748   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C3538749:Myeloma [Intellectual Product]
   741   C1291777:Protein antigen [Immunologic Factor]
Processing 00000000.tx.125: Proc Natl Acad Sci U S A. 

Phrase: "Proc Natl Acad Sci U S A."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   845   C0041703:U.S.A. [Geographic Area]
           U S
Processing 00000000.tx.126: 1972;69: 1540-1544.[Abstract] Tatsumi T, Kierstead LS, Ranieri E, et al. 

Phrase: "1972"

Phrase: ";69"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450388:69 [Intellectual Product]

Phrase: ":"

Phrase: "1540-1544."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Tatsumi T,"

Phrase: "Kierstead LS,"

Phrase: "Ranieri E,"

Phrase: "et al."
Processing 00000000.tx.127: Disease-associated bias in T helper type 1, (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRB1*0401+ patients with renal cell carcinoma of melanoma. 

Phrase: "Disease-associated bias in T helper type 1, (Th1)"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   744   C0242568:Bias [Idea or Concept]
   744   C1504315:Bias [Bird]
   711 E C1061346:Bia [Eukaryote]
   711 E C1704746:BIA [Diagnostic Procedure]

Phrase: "/Th2 CD4+ T cell responses against MAGE-6"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   744   C0871261:responses [Organism Attribute]
   711 E C1704632:Response [Finding]
   711 E C1706817:Response [Intellectual Product]
   711 E C2911692:Response [Mental Process]

Phrase: "in HLA-DRB1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0122040:HLA DRB1 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1705258:HLA DRB1 [Gene or Genome]
   861   C1837204:DRB1 [Gene or Genome]

Phrase: "*0401+ patients with renal cell carcinoma of melanoma."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.128: J Exp Med. 

Phrase: "J Exp Med."
Processing 00000000.tx.129: 2002;196: 619-628.[Abstract/Free FullText] Bendandi M, Gocke CD, Kobrin CB, et al. 

Phrase: "2002"

Phrase: ";196"

Phrase: ":"

Phrase: "619-628."

Phrase: "[Abstract/Free FullText"

Phrase: "] Bendandi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Gocke CD,"

Phrase: "Kobrin CB,"

Phrase: "et al."
Processing 00000000.tx.130: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. 

Phrase: "Complete"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Complete [Qualitative Concept]

Phrase: "molecular remissions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0544452:remissions [Finding]
   861   C0687702:remissions [Neoplastic Process]

Phrase: "induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor"
Meta Candidates (Total=18; Excluded=0; Pruned=0; Remaining=18)
   820   C0314597:Colony-stimulating factor, granulocyte-monocyte [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   792   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   775   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   775   C0079460:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   754   C0440740:Granulocyte-specific [Cell]
   738   C0018183:granulocyte [Cell]
   738   C0026473:Monocyte [Cell]
   738   C0030705:*^patient [Patient or Disabled Group]
   738   C0042196:Vaccination [Therapeutic or Preventive Procedure]
   738   C0205263:Induced [Functional Concept]
   738   C0205369:Specific [Qualitative Concept]
   738   C0332287:Plus [Qualitative Concept]
   738   C0439158:colony [Quantitative Concept]
   738   C1521761:Factor [Functional Concept]
   738   C1552740:specific [Intellectual Product]
   738   C1947989:Colony [Cell]
   738   C1948023:Stimulating [Natural Phenomenon or Process]
   738   C2827422:Factor [Conceptual Entity]

Phrase: "against lymphoma."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024299:Lymphoma [Neoplastic Process]
Processing 00000000.tx.131: Nat Med. 

Phrase: "Nat Med."
Processing 00000000.tx.132: 1999;5: 1171-1177.[CrossRef][Medline] [OrderarticleviaInfotrieve] Adelchi Ruffini P, Neelapu SS, Kwak LW, Biragyn A. 

Phrase: "1999"

Phrase: ";5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ":"

Phrase: "1171-1177."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Adelchi Ruffini P,"

Phrase: "Neelapu SS,"

Phrase: "Kwak LW,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1415842:LW [Gene or Genome]

Phrase: "Biragyn A."
Processing 00000000.tx.133: Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. 

Phrase: "Idiotypic vaccination for B-cell malignancies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: "as a model"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3161035:Model [Intellectual Product]

Phrase: "for therapeutic cancer vaccines"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   913   C0301521:therapeutic vaccines [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   901   C0376659:Cancer Vaccines [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0042210:Vaccines [Immunologic Factor,Pharmacologic Substance]
   793 E C1552558:Vaccine [Intellectual Product]

Phrase: ":"

Phrase: "from prototype protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "to second generation vaccines."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0042210:Vaccines [Immunologic Factor,Pharmacologic Substance]
   793 E C1552558:Vaccine [Intellectual Product]
Processing 00000000.tx.134: Trends Hematol Oncol. 

Phrase: "Trends"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040833:trends [Temporal Concept]
  1000   C1521798:Trends [Temporal Concept]

Phrase: "Hematol Oncol."
Processing 00000000.tx.135: 2002;87: 989-1001. 

Phrase: "2002"

Phrase: ";87"

Phrase: ":"

Phrase: "989-1001."
Processing 00000000.tx.136: Rasmussen T, Jensen L, Johnsen HE. 

Phrase: "Rasmussen T,"

Phrase: "Jensen L,"

Phrase: "Johnsen"

Phrase: "HE."
Processing 00000000.tx.137: The clonal hierarchy in multiple myeloma. 

Phrase: "The clonal hierarchy in multiple myeloma."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0699032:Hierarchy [Functional Concept]
Processing 00000000.tx.138: Acta Oncol. 

Phrase: "Acta Oncol."
Processing 00000000.tx.139: 2001;39: 765-770. 

Phrase: "2001"

Phrase: ";39"

Phrase: ":"

Phrase: "765-770."
Processing 00000000.tx.140: Billadeau D, Ahmann G, Greipp P, Van NB. 

Phrase: "Billadeau D,"

Phrase: "Ahmann G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Greipp P,"

Phrase: "Van NB."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0919442:NB [Gene or Genome]
   861   C1705347:NB [Gene or Genome]
Processing 00000000.tx.141: The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. 

Phrase: "The bone marrow of multiple myeloma patients"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   778   C0005953:Bone Marrow [Tissue]
   748   C0086590:Marrow [Food]
   748   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   748   C0376152:Marrow [Body Part, Organ, or Organ Component]
   748   C0391978:Bone [Tissue]
   748   C1266908:Bone [Body Part, Organ, or Organ Component]
   748   C1266909:Bone [Body System]
   748   C1546708:Marrow [Intellectual Product]
   746 E C1708973:Medullary Bone [Tissue]

Phrase: "contains"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "B cell populations at different stages of differentiation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0032659:Population [Quantitative Concept]
   744   C1257890:Population [Population Group]

Phrase: "that"

Phrase: "are"

Phrase: "clonally"

Phrase: "related to the malignant plasma cell."
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   790   C0032112:Plasma cell [Cell]
   783   C0334227:Malignant Cell [Cell]
   753   C0007634:Cell [Cell]
   753   C0032105:Plasma [Body Substance]
   753   C0205282:Malignant [Qualitative Concept]
   753   C0334590:MALIGNANT [Neoplastic Process]
   753   C0439849:Related [Qualitative Concept]
   753   C0445223:Related [Finding]
   753   C1269647:Cell [Cell]
   753   C1533592:MALIGNANT [Neoplastic Process]
   753   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
   719 E C0163712:Relate [Organic Chemical]
Processing 00000000.tx.142: J Exp Med. 

Phrase: "J Exp Med."
Processing 00000000.tx.143: 1993;178: 1023-1031.[Abstract] Corradini P, Boccadoro M, Voena C, Pileri A. 

Phrase: "1993"

Phrase: ";178"

Phrase: ":"

Phrase: "1023-1031."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Corradini P,"

Phrase: "Boccadoro M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Voena C,"

Phrase: "Pileri A."
Processing 00000000.tx.144: Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. 

Phrase: "Evidence for a bone marrow B cell"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0332120:Evidence [Functional Concept]

Phrase: "transcribing"

Phrase: "malignant plasma cell VDJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   708   C0334227:Malignant Cell [Cell]

Phrase: "joined to C mu sequence"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0004793:Sequence [Nucleotide Sequence]
   760   C0162326:Sequence [Nucleotide Sequence]
   760   C0162327:Sequence [Nucleotide Sequence]
   760   C0347978:Mu [Intellectual Product]
   760   C1519249:Sequence [Functional Concept]

Phrase: "in immunoglobulin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1621846:immunoglobulin [Molecular Function]

Phrase: "(IgG)-"

Phrase: "and"

Phrase: "IgA-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2825347:IgA [Immunologic Factor,Pharmacologic Substance]

Phrase: "secreting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1327616:Secreting [Cell Function]

Phrase: "multiple myelomas."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0026764:Myelomas, Multiple [Neoplastic Process]
           myelomas
   861   C0439064:Multiple [Quantitative Concept]
   827 E C3538749:Myeloma [Intellectual Product]
Processing 00000000.tx.145: J Exp Med. 

Phrase: "J Exp Med."
Processing 00000000.tx.146: 1993;178: 1091-1096.[Abstract] Reiman T, Seeberger K, Taylor BJ, et al. 

Phrase: "1993"

Phrase: ";178"

Phrase: ":"

Phrase: "1091-1096."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Reiman T,"

Phrase: "Seeberger K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Taylor BJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005005:BJ [Geographic Area]

Phrase: "et al."
Processing 00000000.tx.147: Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. 

Phrase: "Persistent preswitch clonotypic myeloma cells"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   806   C0333843:Myeloma cell [Cell]
   804   C0007634:Cells [Cell]
   804   C0026764:Myeloma [Neoplastic Process]
   804   C3282337:Cells [Cell]
   804   C3538749:Myeloma [Intellectual Product]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]

Phrase: "correlate with decreased survival"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0038952:Survival [Activity]
   770   C0205216:Decreased [Quantitative Concept]
   770   C0220921:survival [Functional Concept]
   770   C0392756:Decreased [Qualitative Concept]
   770   C0442797:decreased [Qualitative Concept]
   737 E C0547047:Decrease [Quantitative Concept]

Phrase: ":"

Phrase: "evidence for isotype"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0332120:Evidence [Functional Concept]

Phrase: "switching within the myeloma clone."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0009013:Clone [Cell]
   760   C0026764:Myeloma [Neoplastic Process]
   760   C1522642:Clone [Tissue]
   760   C3538749:Myeloma [Intellectual Product]
   726   C1707719:Switch [Manufactured Object]
Processing 00000000.tx.148: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.149: 2001;98: 2791-2799.[Abstract/Free FullText] Rasmussen T, Jensen L, Honore L, Andersen H, Johnsen HE. 

Phrase: "2001"

Phrase: ";98"

Phrase: ":"

Phrase: "2791-2799."

Phrase: "[Abstract/Free FullText"

Phrase: "] Rasmussen T,"

Phrase: "Jensen L,"

Phrase: "Honore L,"

Phrase: "Andersen H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Johnsen"

Phrase: "HE."
Processing 00000000.tx.150: Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. 

Phrase: "Circulating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0175630:Circulating [Functional Concept]

Phrase: "clonal cells in multiple myeloma"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   797   C0333843:cells myeloma [Cell]
   770   C0009013:Clone Cells [Cell]
   760   C0007634:Cells [Cell]
   760   C3282337:Cells [Cell]
   726 E C1269647:Cell [Cell]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "express"

Phrase: "CD34 mRNA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "as"

Phrase: "measured by single-cell"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   770   C0007634:Cell [Cell]
   770   C0037179:Single [Population Group]
   770   C0087136:single [Finding]
   770   C0205171:Single [Quantitative Concept]
   770   C0444706:Measured [Qualitative Concept]
   770   C1269647:Cell [Cell]
   770   C1704653:Cell [Medical Device]
   770   C1948049:Cell [Spatial Concept]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]

Phrase: "and"

Phrase: "real-time RT-PCR assays."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   917   C1709846:REAL-TIME POLYMERASE CHAIN REACTION ASSAY [Molecular Biology Research Technique]
           Real-Time Polymerase Chain Reaction
   861   C0034746:time reaction [Temporal Concept]
   845   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   795   C0337112:Chain [Manufactured Object]
   795   C0443286:Reaction [Functional Concept]
   795   C1114821:Reaction [Clinical Attribute]
   795   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   795   C1524075:Chain [Idea or Concept]
   762   C0005507:Assay [Laboratory Procedure]
   762   C0243073:assay [Qualitative Concept]
   762   C1510438:Assay [Laboratory Procedure]
Processing 00000000.tx.151: Br J Haematol. 

Phrase: "Br J Haematol."
Processing 00000000.tx.152: 1999;107: 818-824.[CrossRef][Medline] [OrderarticleviaInfotrieve] Rasmussen T, Poulsen TS, Honore L, Johnsen HE. 

Phrase: "1999"

Phrase: ";107"

Phrase: ":"

Phrase: "818-824."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Rasmussen T,"

Phrase: "Poulsen TS,"

Phrase: "Honore L,"

Phrase: "Johnsen"

Phrase: "HE."
Processing 00000000.tx.153: Quantitation of minimal residual disease in multiple myeloma using an allele specific real-time PCR assay. 

Phrase: "Quantitation of minimal residual disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1709793:Quantitation [Quantitative Concept]

Phrase: "in multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an allele specific real-time PCR assay."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   923   C1709846:REAL-TIME POLYMERASE CHAIN REACTION ASSAY [Molecular Biology Research Technique]
           Real-Time Polymerase Chain Reaction
   836   C0034746:time reaction [Temporal Concept]
   835   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   793   C0005507:Assay [Laboratory Procedure]
   793   C0243073:assay [Qualitative Concept]
   793   C0337112:Chain [Manufactured Object]
   793   C0443286:Reaction [Functional Concept]
   793   C1114821:Reaction [Clinical Attribute]
   793   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   793   C1510438:Assay [Laboratory Procedure]
   793   C1524075:Chain [Idea or Concept]
Processing 00000000.tx.154: Exp Hematol. 

Phrase: "Exp Hematol."
Processing 00000000.tx.155: 2000;28: 1039-1045.[CrossRef][Medline] [OrderarticleviaInfotrieve] sterborg A, Yi Q, Bergenbrant S, Holm G, Lefvert A-K, Mellstedt H. 

Phrase: "2000"

Phrase: ";28"

Phrase: ":"

Phrase: "1039-1045."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] sterborg A,"

Phrase: "Yi Q,"

Phrase: "Bergenbrant S,"

Phrase: "Holm G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Lefvert A-K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: "Mellstedt H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.156: Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. 

Phrase: "Idiotype-specific T cells in multiple myeloma stage I"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   764   C0039194:T-Cells [Cell]
   762   C0333843:cells myeloma [Cell]
   742   C0007634:Cells [Cell]
   742   C3282337:Cells [Cell]
   708 E C1269647:Cell [Cell]
   708 E C1704653:Cell [Medical Device]
   708 E C1948049:Cell [Spatial Concept]

Phrase: ":"

Phrase: "an evaluation by four different functional tests."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0178628:evaluation tests [Research Activity]
   774   C0278372:Functional evaluation [Diagnostic Procedure]
   748   C0220825:Evaluation [Functional Concept]
   748   C1261322:Evaluation [Health Care Activity]
Processing 00000000.tx.157: Br J Haematol. 

Phrase: "Br J Haematol."
Processing 00000000.tx.158: 1995;89: 110-116.[Medline] [OrderarticleviaInfotrieve] Marchand M, van Baren N, Weynants P, et al. 

Phrase: "1995"

Phrase: ";89"

Phrase: ":"

Phrase: "110-116."

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Marchand M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "van Baren N,"

Phrase: "Weynants P,"

Phrase: "et al."
Processing 00000000.tx.159: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. 

Phrase: "Tumor regressions"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   983   C1718423:Tumor regression [Organism Attribute]
   861   C0684320:regressions [Pathologic Function]
   861   C0684321:regressions [Mental Process]

Phrase: "observed in patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1441672:Observed [Functional Concept]

Phrase: "with metastatic melanoma"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0278883:Metastatic melanoma [Neoplastic Process]
   861   C0025202:melanoma [Neoplastic Process]
   861   C0036525:Metastatic [Functional Concept]
   861   C1522484:metastatic [Quantitative Concept]
   861   C2984289:Melanoma [Functional Concept]
   861   C3539018:Melanoma [Intellectual Product]

Phrase: "treated with an antigenic peptide"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   760   C0030956:Peptide [Amino Acid, Peptide, or Protein]
   760   C1522326:Treated [Functional Concept]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "encoded by gene MAGE-3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   844   C1706471:MAGE-3 Gene [Gene or Genome]
   760   C0017337:Gene [Gene or Genome]
   760   C0679058:encoded [Mental Process]
   760   C1709015:MAGE [Organization]
   760   C2700640:Encoded [Activity]

Phrase: "and"

Phrase: "presented by HLA-A1."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   833   C0019731:HLA-A1 [Immunologic Factor]
   770   C0449450:Presented [Idea or Concept]
   737 E C0150312:Present [Quantitative Concept]
Processing 00000000.tx.160: Int J Cancer. 

Phrase: "Int J Cancer."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0006826:Cancer [Neoplastic Process]
   827   C0998265:Cancer [Eukaryote]
   827   C1306459:Cancer [Finding]
Processing 00000000.tx.161: 1999;80: 219-230.[CrossRef][Medline] [OrderarticleviaInfotrieve] Massaia M, Borrione P, Battaglio S, et al. 

Phrase: "1999"

Phrase: ";80"

Phrase: ":"

Phrase: "219-230."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Massaia M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Borrione P,"

Phrase: "Battaglio S,"

Phrase: "et al."
Processing 00000000.tx.162: Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 

Phrase: "Idiotype vaccination in human myeloma"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C0199798:Human vaccination [Therapeutic or Preventive Procedure]
   760   C0042196:Vaccination [Therapeutic or Preventive Procedure]

Phrase: ":"

Phrase: "generation of tumor-specific immune responses"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0079411:Generation [Temporal Concept]
   753   C3146294:Generation [Activity]

Phrase: "after high-dose chemotherapy."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.163: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.164: 1999;94: 673-683.[Abstract/Free FullText] Galea HR, Cogn M. 

Phrase: "1999"

Phrase: ";94"

Phrase: ":"

Phrase: "673-683."

Phrase: "[Abstract/Free FullText"

Phrase: "] Galea HR,"

Phrase: "Cogn M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.165: GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model. 

Phrase: "GM-CSF"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
  1000   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
  1000   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   937   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   937   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   933   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0018183:granulocyte [Cell]
   804   C0024432:macrophage [Cell]
   804   C0439158:colony [Quantitative Concept]
   804   C1521761:Factor [Functional Concept]
   804   C1947989:Colony [Cell]
   804   C1948023:Stimulating [Natural Phenomenon or Process]
   804   C2827422:Factor [Conceptual Entity]

Phrase: "and"

Phrase: "IL-12 production by malignant plasma cells"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   814   C1819439:interleukin-12 production [Organism Function]
   788   C0312852:Plasma cell production [Organ or Tissue Function]
   774   C3159141:interleukin production [Organism Function]
   748   C0033268:production [Occupational Activity]

Phrase: "promotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "cell-mediated immune responses against monoclonal Ig determinants"
Meta Candidates (Total=17; Excluded=3; Pruned=0; Remaining=14)
   812   C1318468:cell immune mediated responses [Cell Function]
   811   C1155250:immunoglobulin mediated immune response [Organism Function]
   770   C0301872:immune responses [Organ or Tissue Function]
   767   C0870868:mediated responses [Mental Process]
   744   C0007634:Cell [Cell]
   744   C0086597:mediated [Social Behavior]
   744   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]
   744   C0439662:Immune [Functional Concept]
   744   C0871261:responses [Organism Attribute]
   744   C1269647:Cell [Cell]
   744   C1704653:Cell [Medical Device]
   744   C1948049:Cell [Spatial Concept]
   717   C0020966:Cell-Mediated Immunity [Organism Function]
   717   C3536823:Cell-mediated Immunity [Cell Function]
   711 E C1704632:Response [Finding]
   711 E C1706817:Response [Intellectual Product]
   711 E C2911692:Response [Mental Process]

Phrase: "in a light chain myeloma model."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C3161035:Model [Intellectual Product]
   756   C0456844:Light chain myeloma [Neoplastic Process]
Processing 00000000.tx.166: Clin Exp Immunol. 

Phrase: "Clin Exp Immunol."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.167: 2002;129: 247-253.[CrossRef][Medline] [OrderarticleviaInfotrieve] Rambaldi A, Lazzari M, Manzoni C, et al. 

Phrase: "2002"

Phrase: ";129"

Phrase: ":"

Phrase: "247-253."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Rambaldi A,"

Phrase: "Lazzari M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Manzoni C,"

Phrase: "et al."
Processing 00000000.tx.168: Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. 

Phrase: "Monitoring of minimal residual disease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0150369:Monitoring [Health Care Activity]
   760   C1516647:monitoring [Research Activity]

Phrase: "after CHOP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945739:chop [Activity]

Phrase: "and"

Phrase: "rituximab in previously untreated patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0393022:rituximab [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "with follicular lymphoma."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0024301:Lymphoma, Follicular [Neoplastic Process]
   861   C0024299:Lymphoma [Neoplastic Process]
   861   C0439682:Follicular [Qualitative Concept]
   861   C1571705:Follicular [Body Part, Organ, or Organ Component]
Processing 00000000.tx.169: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.170: 2002;99: 856-862.[Abstract/Free FullText]

Phrase: "2002"

Phrase: ";99"

Phrase: ":"

Phrase: "856-862."

Phrase: "[Abstract/Free FullText"

Phrase: "]"

